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ABSTRACT 
Each gene or protein has its own function which, when combined with others, allows the 
group to perform more complex behaviors, e.g. carry out a particular cellular task 
(functional module) or affect a particular disease phenotype (disease module). One of 
the major challenges in systems biology is to reveal the roles of genes or proteins in 
functional modules or disease modules.  
In the first part of the dissertation, I present a data-driven method, Correlation Set 
Analysis (CSA), for comprehensively detecting active regulators in disease populations 
by integrating co-expression analysis and specific types of literature-derived causal 
relationships. Instead of investigating the co-expression level between regulators and 
their targets, I focus on coherence of regulatees of a regulator, e.g. downstream targets 
of a transcription factor. Using simulated datasets I show that my method can reach high 
true positive rate and true negative rate (>80%) even the regulatory relationships is weak 
(only 20% of regulatees are co-expressed). Using three separate real biological datasets 
 v 
I was able to recover well-known and as- yet undescribed, active regulators for each 
disease population.  
In the second part of the dissertation, I develop and apply a new computational algorithm 
for detecting modules of functionally related genes that are likely to drive malignant 
transformation. The algorithm takes as input the identity and locations of a small number 
of known oncogenes (a seed set) on a human genome functional linkage network (FLN). 
It then searches for a boundary surrounding a gene set encompassing the seed, such 
that the magnitude of the difference in linkage weights between interior-interior gene 
pairs, and interior-exterior gene pairs is maximized. Starting with small seed sets for 
breast and ovarian cancer, I successfully identify known and novel drivers in both cancer 
types.  
In the third part of the dissertation, I propose a module based approach for expanding 
manually curated functional modules. I use the KEGG pathway database as an example 
and the results show that my approach can successfully suggest both validated pathway 
members (genes that are assigned to a particular pathway by other manually curated 
pathway databases) and novel candidate pathway genes. 
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Chapter 1. Introduction 
1.1 What constitutes a module in a biological network? 
The interaction between genes, transcripts, proteins, and external stimuli is generally 
complex. One gene can be regulated by one or more proteins, and conversely, one 
protein can regulate several genes [1, 2]. The interaction between genes and proteins 
can be presented by an interaction network, such as a protein-protein interaction (PPI) 
network, a transcriptional regulation network, a metabolic network, or functional linkage 
network (FLN). Most real-world networks, including the biological networks we 
mentioned above, have some basic properties in their structure which cannot be found in 
random networks. First is the special behavior of degree distribution, which is the 
fraction of nodes having n links (n=0, 1, 2…). In a network that is generated by a 
stochastic process, the majority of nodes have similar number of links and only a small 
percentage of nodes have extremely large or small number of links. Therefore the 
degree distribution of a random network follows the binomial distribution or Poisson 
distribution in the limit of large graph size [3]. Real networks, however, have a power law 
distribution of degrees, which means they are scale free networks [4]. In a scale free 
network, most nodes only have a few links and relatively small number of nodes are 
highly connected (hubs). These hubs usually serve special roles in a network.  
The second property is the modularity structure of a network. Modules are highly 
interconnected local regions in a network. In biological networks, modules could be 
groups of genes or proteins that form a protein complex, carry out a similar function, or 
contribute to a certain phenotype. In 2011, Barabasi et al. concluded that there were 
three basic modularity concepts in a biological network: a topological module, a 
functional module, and a disease module (Figure 1-1) [5]. Topological modules are 
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locally dense regions on a network. The nodes in this module have a higher tendency to 
connect with nodes within the module than nodes outside the module. Functional 
modules represent groups of nodes that are involved in the similar or related functions. A 
disease module represents a group of nodes (genes or proteins) that contribute to the 
same disease. Typically, genes in a disease module share mutations, structure 
variations, or expression abnormalities linked to a particular disease phenotype. These 
modularity concepts lead to different methods for studying modules in a biological 
network. The first one is to identify a module for a particular disease phenotype. In this 
thesis, we focus on identifying driver modules in cancer. The second method is to predict 
new functional modules or suggest new members to an existing functional module.  
 
Figure 1-1 Modularity concepts in biological networks. (a) Topological modules are locally 
dense regions on a network. The nodes in this module have a higher tendency to connect with 
nodes within the module than nodes outside the module. (b) Functional modules are groups of 
nodes with related functions. The nodes in a functional module tend to interact with nodes in the 
same functional module than nodes outside the module. (c) A disease module is a group of 
nodes (genes or proteins) that contribute to the same disease. The mutations, structurural 
variations, or expression abnormalities of those genes/proteins are related to a particular disease.  
Figure adapted from Barabasi et al., Nature Review, 2011. 
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1.2 Modules in cancer 
Cancer is a genetic, epigenetic and phenotypic heterogeneous disease. Genetic and 
epigenetic heterogeneity means cancer may arise from a multitude of point mutations, 
copy number variations or epigenetic modifications. For example, Lafrate et al. found 
that malignant brain tumors contain amplifications of three different receptor tyrosine 
kinases (EGFR, MER, PDGFRA) in different tumor cells [6]. Breast cancer is a well-
known example of phenotypic heterogeneous disease that has diverse morphology, 
expression profiles and immunohistochemical patterns [7, 8]. In the past few decades, 
cancer research has made remarkable advances. Hanahan and Weinberg first proposed 
six hallmarks of cancer in 2000, which includes: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed cell death 
(apoptosis), limitless replicative potential, sustained angiogenesis, and tissue invasion 
and metastasis (Figure 1-2a) [9]. In 2011, they added two emerging hallmarks – 
reprogramming of energy metabolism and evading immune destruction (Figure 1-2b) 
[10]. 
 
 
 
 
 
Figure 1-2. Hallmarks of cancer. Figure adapted from Hanahan and Weinberg, Cell, 2000 and 
2011. 
(a) (b) 
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A central goal in cancer research is to distinguish mutations that drive the initiation and 
development of a tumor (drivers) from the many other mutations that are unrelated to 
transformation (passengers). This problem is difficult because the unidentified driver 
mutations occur infrequently, and must be identified from within a much larger pool of 
mutations that have no bearing on cancer. Moreover, with the advent of very high 
throughput sequencing, the background pool is increasing rapidly. Until recently, 
researchers have only revealed ~140 drivers [11]. Since knowledge of cancer causing 
alterations is essential to the identification of therapeutic targets, solving the driver 
identification problem is a critical as well as a difficult challenge. Progress toward its 
solution will not only add substantially to our understanding of cancer cell biology, but 
should also greatly increase therapeutic options.  
1.3 Current driver identification approaches 
Driver identification has been approached in a number of ways. The most widely used 
approach attempts to identify genes mutated more frequently in cancer cells than 
background mutation rate [12–15]. Those methods assume that a mutation that drives 
cancer should confer a growth advantage to tumor cells. They perform well on detecting 
popular driver genes, but may neglect drivers with low mutation frequency. Another 
widely adapted idea is to identify genes having high rate of functional mutations, i.e. non-
silent mutations [16–18]. The assumption underlying this approach is that non-silent 
mutations are more likely than silent mutations to be potential drivers because non-silent 
mutations usually have higher impact on protein functions. Still, many other approaches 
are developed to provide a solution for driver identification, including searching for genes 
with a regional clustering of mutations [19], or genes having mutations in specific 
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functional residues, e.g. phosphorylation sites [20]. Above approaches, however, only 
consider abnormal mutations in each gene and ignore the interaction between genes.  
1.4 Module based approaches for predicting drivers in cancer 
Recent years, there are other computational methods, such as MEMo and PARADIGM, 
they move the direction from identifying individual drivers to pathways that are 
dysregulated in cancer [21, 22]. However, one criticism of pathway approaches is that 
they ignore all the genes that are not currently in manually curated pathways. 
To address this problem, in chapter 2 we first demonstrate how to identify active 
regulators in diseases by integrating a manually curated interaction network with 
expression information. The network we used in chapter 2 consists of relationships that 
describe the flow of causality directed from a specific regulator to a specific regulatee 
and covers ~10,000 genes. We restrict regulatees at transcript level only as because the 
expression data we used is measuring the activities of regulatees at the transcript level. 
In contrast, regulators can include transcript and protein levels. The more detail 
definitions and examples of regulators and regulatees will be illustrated in chapter 2. We 
present a novel algorithm that takes a regulator and its downstream regulatees as a 
regulatory module and incorporates expression data to identify candidate active 
regulators in diseases. This is based on the hypothesis that in most cases an active 
regulator under a given condition should activate or inhibit a subset of its regulatees. 
Using three separate real biological datasets we were able to recover well known and as 
yet undescribed, active regulators for each disease population.  
Next, we focus on identifying “drivers” in cancer by applying a module based approach 
to a weighted functional linkage network. In chapter 3, we present a multifaceted 
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computational approach –very different from those currently in use -- that draws upon 
multiple data sources to help solve this problem. The algorithm is based on the idea that 
oncogenes clustered on an evidence weighted functional linkage network are embedded 
in a field of genes and pathways that are likely to be associated with cancer cell 
physiology. More specifically, we present a method for determining the boundary of the 
field, thereby obtaining a module that is functionally rich in drivers, and enabling the 
identification of new oncogene candidates.  
1.5 Module based approach for expanding manually curated functional modules 
Functional modules are routinely identified based on so-called Gene Set Analysis (GSA) 
methods and a number of statistical procedures have been proposed, e.g. DAVID, 
GSEA, PWEA, MIRTFnet [23–28]. Most of the current functional modules, especially 
pathways, used in those GSA methods are from manually curated sources [29–34]. 
These manually curated functional modules offer highly confident and clearly annotated 
functions of modules and elements in each module. Because of this, however, these 
annotations are limited to both incomplete current biological knowledge and the 
requirement of substantial manpower. Due to this, the manually curated functional 
modules are usually small and the coverage is low. Another issue plaguing manually 
curated functional modules is the lack of standard criteria when collecting and translating 
the data from literature. Therefore, the same pathway or ontology may have different 
elements in different databases. For example, the well-known citric acid (TCA) cycle has 
19 genes in Reactome and 31 genes in KEGG, yet has only 8 genes in BioCarta. Seven 
of these genes are treated as members of TCA cycle in all three databases but many 
more genes are assigned to TCA cycle by only one or two databases. In the last chapter 
of this thesis, we demonstrate how a module based approach can improve our 
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knowledge of current manually defined functional modules. We use the KEGG pathway 
database as an example and successfully suggest new members with strong evidence 
supports to KEGG pathways. 
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Chapter 2. Correlation Set Analysis: Detecting active regulators in disease 
populations using prior causal knowledge 
2.1 Introduction 
Fundamental functions of living cells are controlled by regulatory relations between 
genes and proteins. Most cell types respond to changes in their environment (e.g. drug 
treatments or disease causing mutations) by altering their transcriptional patterns. More 
than a decade ago, it became possible to measure snapshots of all transcript levels in a 
given tissue sample using microarray technology. Since then, advances in technology 
have multiplied and the cost of experiments has decreased significantly. As a 
consequence, cell lines, animal models as well as clinical subjects in drug trials or in the 
general population [35] have been characterized on a molecular level.  One crucial 
problem in such studies is the detection of active key regulators; i.e. genes or proteins 
that causally affect expression of downstream genes or proteins in the study population.  
The detection of regulators or regulatory networks from the primary data alone has been 
studied extensively. Network reconstruction can be approached by identifying 
correlations in expressed genes [36], using any number of methods including those 
based on information theory [37], Bayesian models [38, 39] and regression models [40]. 
However, all purely expression-based methods assume that the expression of regulators 
and targets are directly (anti-) correlated or at least not independent of each other. Smet 
et al. showed that such models of high correlation between regulator and target don’t 
match the actual regulator-target relation captured in RegulonDB [41]. One of the 
possible explanations is that a regulator, even a transcription factor, itself is not 
necessarily co-expressed with its targets, especially when the regulatory relation of the 
regulator and the targets is complex [42] or regulation acts beyond the transcriptional 
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level, e.g. by phosphorylation. This suggests that in many cases the activity of regulator 
cannot be inferred from transcriptional data alone. 
While methods to infer causal regulators directly from heterogeneous primary data types 
have been proposed and successfully validated in some cases [43], [44], these methods 
necessarily require very large sample sizes and a mix of different data types, e.g. 
genomic and transcriptomic data. Even when such large data sets are available, the 
choice of which hypothesis to pursue in follow-up experiments might not be easy to 
make as such methods usually don’t relate their conclusions back to already known 
biological facts. 
In this study we are interested in a method that suggests active regulators and 
corresponding perturbation experiments for a population based on expression data 
alone. With that goal in mind the above discussion suggests that investigating coherence 
between regulatee pairs rather than regulator-regulatee pairs might be more suitable for 
evaluating the activity of a given regulator. To associate regulatee coherence to a 
possibly only non-transcriptionally controlled regulator requires the use of prior 
knowledge. 
Our knowledge of molecular biology has increased dramatically over the past several 
decades as evidenced by the 20 million articles currently indexed by the National Library 
of Medicine [45]. This immense body of knowledge contains many experiments that 
define the response of a biological system to a stimulus, e.g. by altering its 
transcriptional state. These experiments can be translated into causal regulatory 
relationships. Whenever the question of causal regulators is relevant (e.g. in finding 
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potential intervention points in ovarian cancer), each experimentally validated finding 
constitutes a hypothesis that can be evaluated based on the data set at hand.  
In contrast to many previous approaches, we rely on a very specific type of prior 
knowledge, namely relationships extracted from the literature that are (a) based on well-
described laboratory experiments, (b) have a citation in the literature, and (c) establish a 
flow of causality; i.e. a directed flow of information form a well-defined perturbation 
experiment to observed molecular changes. Consequently, our method does not rely on 
association but on established causation and should be well-suited to providing 
hypotheses about the causal regulators that are active in a given dataset. This 
specifically allows us to make statements about regulators that are not limited to 
activation by changes in transcript abundance, but can include changes in protein 
abundance or post-translational modifications.  
Prior biological knowledge has been used successfully in many contexts before. 
Relevant functional terms, dysregulated pathways in diseases as well as active miRNAs 
and transcription factors are routinely predicted based on so-called Gene Set Analysis 
(GSA) methods and a number of statistical procedures have been proposed, e.g. [23–
27]. However, virtually all such methods focus on differential gene expression between 
two conditions as opposed to coordinated changes in a subject population. The situation 
is similar for methods that that utilize networks of prior information [46, 47].  A class of 
methods that has been proposed to detect subnetworks co-expressed across a 
population [48, 49] is related in that it utilizes expression data across all conditions in 
conjunction with a network. However, such methods aim at finding coherence between 
expression correlation and distance in the network in general. Our goal is to specifically 
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assess whether a regulator is likely to be active based a given expression data set and 
consequently point the researcher to relevant perturbation experiments in the literature. 
To this end, we introduce the Correlation Set Analysis (henceforth referred to as CSA) 
method in the following, provide evidence that it performs well on simulated datasets, 
and apply it to three different disease settings: ovarian cancer [50], metabolic disease 
[51], and diffuse large B-cell lymphoma (DLBCL) [52].  
 
Figure 2-1. Schematic illustration of the Correlation Set Analysis (CSA) method.  
 
2.2 Materials and methods 
We identify regulators that are active under a given condition if (a fraction α of) its known 
targets show (a specified degree β of) correlated transcriptional change. This method 
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does not infer novel regulatory relationships, but rather selects from a library of 
experimentally defined relationships which regulators test as active in the population of 
interest. Figure 2-1 provides an overview of CSA. We elaborate on each step below. 
2.2.1 Constructing the causal network 
The suggested method relies on a causal network to define regulators and regulatees 
and can only be as good as the encoded biological facts. The causal network consists of 
relationships that (a) are based on well-described laboratory experiments, (b) have a 
citation in the literature, and (c) most importantly, establish the flow of causality directed 
from a specific regulator to a specific regulatee. Consequently, our method does not rely 
only on association, but on established causation. For example, consider the following 
statements extracted from two articles represented in the Ingenuity [53] data: 
1) “Binding of mouse Fyn protein and mouse Cnr1 (Pcdha4) protein occurs in 
mouse brain.” (PMID 9655502) 
2) “Blockade of CB1 (CNR1) increases expression of hepatic lipase (LIPC).” (PMID 
20110567) 
While statement 1 asserts a biologically correct binding event, it doesn’t imply a directed 
flow of information and it is unclear what consequences the binding event has. In 
contrast, statement 2 describes a perturbation experiment that causally leads to 
observed changes. Only statement 2 allows for a meaningful definition of regulator and 
regulatee. Ultimately, the use of causal statements facilitates the interpretation of results 
and focuses the analysis on potential upstream drivers of the process under 
consideration. 
13 
 
Regulators and regulatees can be of different molecular types and include transcript 
levels, protein levels, protein activities and phosphorylation states. For the purpose of 
this method, we restrict our causal network to transcript regulatees as this is consistent 
with the population measures analyzed.  In contrast, regulators include transcript and 
protein levels as well as protein modifications and activities. For CSA, we abstract these 
different forms into an undifferentiated node in the causal network based on their Entrez 
identifier [54]. 
It is important to note that the results of such transcriptional perturbation experiments do 
not necessarily capture direct physical relationships. In the example above, the increase 
in transcript levels of LIPC is certainly mediated by a cascade of other signaling 
molecules. Consequently, the CSA method is not limited to transcription factors as 
regulators, but encompasses many other classes of molecules amenable to perturbation 
experiments. 
To ensure the reliability of the data, we only include manually curated statements. The 
substrate for the causal network is licensed from two commercial sources, Selventa Inc. 
[55] and Ingenuity Inc. [53] and, after filtering and post-processing, reduces to 6,942 
regulators and 11,134 regulatees. Selventa Inc. has recently launched an initiative to 
provide access to a significant amount of causal information to academic researchers 
through the BEL-Portal (http://belportal.org). Among 6,942 regulators, 3,002 are proteins 
or mRNAs and 3,940 are chemical compounds or environmental factors (e.g. internal 
metabolites such as glucose or pyruvate, approved drugs such as Rosiglitazone or 
Doxorubicin, or environmental conditions such as hypoxia or oxidative stress). As 
described above from this we selected the subset of proteins and mRNA regulators. 
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After removing self-regulation and regulators that only have one regulatee, the causal 
network reduces to 1,783 regulators and 10,097 regulatees. 
2.2.2 Scoring putative regulators  
We assumed an active regulator under a given condition should activate or inhibit a 
subset of its regulatees. Across a set of conditions (e.g. in a patient population), this 
relationship should become apparent in a coordinated change in expression levels for 
regulatees downstream of an active regulator. We used different scoring functions to 
identify active regulators.  
2.2.2.1 Mean scoring function 
Pearson’s correlation coefficient is one of the most widely used measures to evaluate 
similarities of gene expression profiles. For an expression dataset with m samples, the 
co-expression level of any two genes X and Y can be calculated by the correlation 
coefficient ),( YXcor . 
∑∑
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, where X  and Y are sample means of gene X and gene Y respectively. 
To assess the expression coherence of regulatee sets, we employed the simple test of 
measuring all pair-wise correlations within each set. Such a coherent regulatee set is 
consistent with the hypothesis that the corresponding regulator is active in the condition 
under consideration.  
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The causal network also specifies the type of regulation (i.e. up-regulation or down-
regulation). Consider two regulatees, X and Y, that are under the control of a common 
regulator. If X and Y are regulated coherently, we expect their transcriptional profiles to 
be correlated. Conversely, if X is up-regulated and Y is down-regulated, we expect their 
profiles to be anti-correlated. We examined the correlation coefficients between up-
regulated regulatees and down-regulated regulatees to test this hypothesis. However, 
we did not observe significant differences between correlation coefficients of regulatees 
regulated in the same direction and regulatees regulated in the opposite direction. Thus, 
we decided to use the absolute value of the correlation coefficient cor in the scoring 
functions. 
One intuitive way of detecting regulators with highly coherent regulatee pairs is to 
examine the average of all absolute correlation coefficients between all pairs of 
regulatees Rx for a regulator R.  
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Here, n is the number of regulatees of the regulator R. Rµ is referred to as the mean 
scoring function in the rest of this paper. 
2.2.2.2 Ratio scoring function 
If we expect that a substantial number of regulatees is affected by an active regulator, a 
test for a shift in mean pair-wise co-expression is sensible. However, we also 
investigated possible scenarios based on the biological data sets described in the results 
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section. Figure 2-2a shows an example distribution of absolute correlation coefficients 
between regulatees which has higher average absolute correlation coefficients in a real 
network than in a randomized network. In this case, the majority of regulatees have 
similar expression patterns, which supports the hypothesis that this regulator is active. In 
some cases we observed a small bump at the high absolute correlation tail (Figure 2- 
2b), which indicates a small set of strongly co-expressed regulatees. This situation is 
more difficult to detect by examining the difference of average correlation coefficients.  
Hence, we propose an alternate way to detect active regulators: scoring regulators 
according to the ratio of highly coherent regulatee pairs over all regulatee pairs (referred 
to as the ratio scoring function).  
)1(
2
−
=
nn
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,where c is the number of regulatee pairs, for a specified regulator R having n 
regulatees,  with absolute correlation coefficient greater than a cutoff. Users can define 
biologically relevant pairs by setting the cutoff to levels appropriate to detect a desired 
effect size (say, correlation coefficient larger than 0.6). In this paper, we fix the cutoff, c, 
at the 95th percentile of the distribution of all pair-wise correlations for a given dataset. 
This alternate score will identify small sets of highly coherent regulatees. The decision 
rule based on Rµ  and RF is described in the next section. 
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Figure 2-2. The example distributions of absolute correlation coefficients between 
regulatees of a regulator detected by different target functions. a) The average absolute 
correlation coefficient between regulatees in the real network (red) is significantly higher than it in 
the random network (blue). b) There is no significant difference between the absolute average 
correlation coefficients in the real network and the random network. However, there is a small 
bump at the right hand side, which means a small subset of highly correlated regulatees. The 
ratio scoring function was designed to detect such small subsets of regulatees. 
 
2.2.3 Assessing statistical significance 
These scoring functions provide rank-ordered lists of all regulators in the causal network 
based on the coherence of their downstream regulatees, and indicate which ones may 
be active. While true signals will tend to lead to high scores, high scores in any given 
result may be due to random noise. We therefore evaluated the statistical significance of 
the scores, Rµ  and RF of a regulator R, using a permutation test in two ways: 
1) Gene permutation randomly assigns transcript profiles to regulatees and, thus, 
compares the score of the regulator R to the distribution of scores attained by 
regulators with the same number of randomly chosen regulatees.  
2) Graph permutation generates a random causal network in which each regulator 
controls the same number of regulatees and each regulatee is controlled by the 
same number of regulators as in the original network.   
18 
 
The corresponding permutation scheme (Graph permutation) is more complex and also 
computationally more intensive. In each permutation, we evaluate SR on a random 
graph with the same degree distribution as our causal network. Randomizing a directed 
graph with a given degree sequence is an active field of research and we adopt a 
method from [56] relying on edge switching.  
More precisely, at every iteration we pick two edges, say (a,b) and (c,d), uniformly at 
random from the set of edges E in the current graph, and replace them with the edges 
(a,d) and (c,b). This operation is known as an edge switch, and preserves the in- and 
out-degree distribution of the graph. If the resulting graph remains simple (no parallel 
edges) and weakly connected, it replaces the current graph. In order to save the 
computationally expensive connectivity checks, a batch of K edge switches can be 
performed before a connectivity check. If the check succeeds, K can be increased, while 
if it fails, K can be decreased. The particular adaptive algorithm we use to update K is 
described in [56]. We also adopt the commonly used rule of thumb [57] for the total 
number of edge switches to perform before declaring our graph to be sufficiently 
randomized, which is to perform an average of 3 edge switches per edge of the initial 
graph. Both permutation approaches assert the statistical significance of a score SR 
under the respective null hypothesis, and thus provide guidance to the biologists as to 
whether a particular regulator received a high score based on chance alone. 
Both permutation approaches assess the statistical significance of a score under the 
respective null hypothesis, and thus provide guidance to the biologist as to whether a 
particular regulator received a high score based on chance alone. Note that the 
permutation of sample labels is not a meaningful option in the scenario of only one 
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population when considering correlation though it is a preferred choice in many gene set 
analysis methods comparing two or more sample populations. 
As the causal network contains more than one thousand potentially active regulators, the 
resulting p-values should be corrected for multiple testing. The false discovery rate 
(FDR) is an intuitive and well-accepted alternative measure of significance that is widely 
applied in similar applications. The Benjamini and Hochberg procedure was used to 
estimate the FDR based on the list of p-values [58]. Finally, CSA reports a results table 
of potentially active regulators (FDR < 0.05) which contains FDR, scores (ratio and 
mean), regulatees coherently up- or down-regulated by the regulator, non-coherently 
expressed regulatees, average correlation coefficient of regulator to regulatees, and the 
number of coherent regulatees. Users can rank regulators by the scores (FR or Rµ ), the 
number of coherent regulatees (nc), or the average correlation coefficient of regulator to 
regulatees ( RRµ ). 
2.2.4 Generating simulated data 
In order to make simulated data follow the distribution of the real data, we generate the 
simulated data based on the ovarian cancer data used in this study by applying the 
Cholesky decomposition method of Iman and Conover [59]. This approach is widely 
used to generate correlated random variables in finance. First, we randomly permute 
sample labels of a gene and repeat this step for all genes. Hence, the mean and 
standard deviation of each gene vector are invariant under permutation. The correlation 
between genes, however, is disrupted. Then, we randomly pick N regulators as test set 
of regulators. Each test regulator Rp can regulate a set of regulatees { }qTTT K1= , T  is 
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an n × m matrix, where n  is the number of regulatees and m  is the number of samples 
(m = 391 in this case). We want to generate a set of new regulatees { }sqss TTT K1= with 
same mean and variance as the original set of regulatees but correlate with each other 
at a desired correlation coefficient ρ . An n × n covariance matrix ∑  s with desired 
correlation coefficient ρ  is created. The ∑  must be symmetric and positive-
semidefinite. Therefore, it can be rewritten as LL ′=∑  by Cholesky decomposition, 
where L is the lower triangular matrix of ∑ with positive diagonal entries. We can get 
“spike-in” regulatee matrix sT with desired correlation coefficients ρ  by postmultiplies T  
by L . Iterate above steps until all regulatees of the test regulators are modified to be 
correlated with correlation coefficient ρ . 
2.2.5 Experimental data 
Expression datasets of adipose tissue and DLBCL are downloaded from the Gene 
Expression Omnibus [60]. Adipose tissue samples from 701 individuals [GEO:GSE7965] 
with a range of age from 18 to 85 and average BMI nearly 30 were used in this study. 
Pretreatment tumor samples from 181 and 233 DLBCL patients [GEO:GSE10846] were 
used in this study. TCGA [35] provides mRNA measurements of serous ovarian cancer 
tissue using 3 array platforms: an Agilent array, and Affymetrix's U133A and exon 
arrays. Where genes are overlapping among the 3 platforms, we would like to combine 
the values into a consensus gene. Here, we follow an approach originally described by 
Verhaak et al.[61]. In short, the consensus gene is estimated using a standard factor 
model based approach: 
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where βˆ and Ψˆ are the platform specific coefficients and error covariance estimates, 
respectively, y is the 3-by-m dimensional gene expression values across the 3 platforms, 
and xˆ is the m-dimensional, unified estimate for a single gene. For complete details, see 
Verhaak, et al.[61]. In those cases where only 2 genes are shared across the 3 
platforms, we take the mean value.  
For all of the 3 datasets, we used LSimpute to impute missing values in the expression 
profiles [62]. We discarded genes that are not included in our causal network and leave 
9,052, 9,950 and 7,673 genes in adipose tissue dataset, DLBCL dataset and ovarian 
cancer dataset respectively.  
2.2.6 Performance metrics 
The receiver operating characteristic (ROC) curves are used to evaluate the 
performance of CSA. The true positive rate and false positive rate used for plotting ROC 
curves are calculated as following: 
negatives False  positives True
positives True
  rate positive True
+
=
 
negatives True  positives False
positives False
  rate positive False
+
=
 
2.3 Results on simulation data 
To assess the sensitivity and specificity of CSA, we generated simulated data sets with 
various characteristics. To retain a realistic scale for the data values, we derived our 
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simulated data from the Ovarian Cancer dataset (see “Materials and Methods”). The 
dataset was derived from 391 ovarian cancer patients in TCGA [50]. To obtain a 
baseline dataset with no signal, we randomly permuted the sample labels for each gene 
vector separately. Consequently, each gene vector retains its original distribution, but 
correlations between gene vectors are disrupted. We labelled n genes as active 
regulators in the simulated data. Each induces expression profiles in p% of its regulatee 
pairs that have a Pearson correlation coefficient of r. Regulators and regulatees are 
defined according to the literature-based causal network described earlier. To evaluate 
CSA with respect to many different signal-to-noise characteristics, we varied the 
percentage of correlated regulatee pairs p in 10% increments from 0% to 100%. 
Similarly, we set the correlation coefficient r to {0.3, 0.4, 0.5, 0.6}. Details on the 
generation of dependent profiles can be found in the Materials and Methods section. 
To test the robustness of the method to sample size, we generated additional datasets 
with a random subset of 20, 100, and 200 patients. Finally, we generated simulated sets 
based on n=10 as well as n=100 embedded active regulators. We found that the 
recovery of true positives was not affected by the number of embedded regulators. We 
therefore fixed the number of embedded regulators in the subsequent examples at 
n=100.  
2.3.1 Evaluation of permutation methods and controlling false positives 
While the scoring functions are able to rank embedded active regulators higher than 
non-active ones, they do not provide an objective cutoff value when investigating the 
biological significance of top results. In order to assess the suitability of our procedures 
to control the FDR, Figure 2-3a shows the false positive rate (for definitions, see 
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“Materials and Methods”) of the two scoring functions with the two permutation methods 
on a representative simulated data set (r=0.5; p=50%). Our procedures are able to 
control the false positive rate effectively based on the estimated FDR while retaining a 
good true positive rate (Figure 2-4). In fact, when the data contains no or limited signal, 
CSA does not report any potentially active regulators at reasonable FDR cutoffs (FDR < 
0.05). The same holds true for runs on randomized networks (data not shown). 
 
Figure2-3. (a) False positive rate of CSA with different parameter settings at different FDR 
levels. (b) ROC curves of mean function and ratio function of low/high and high/low 
simulated data. (a) The plot clearly shows that the estimated FDR can well control false positive 
rate of CSA. Both scoring functions with graph permutation reach low false positive rate when 
applying a reasonable FDR cutoff (FDR < 0.05). (b) The ROC curves suggests that the ratio 
scoring function reaches better true positive rate at the expense of a similar gain in false positive 
rate on datasets that contain few highly correlated regulatees. 
 
Figure 2-3a also illustrates that Graph permutation is preferable to Gene permutation. 
ROC curves of Graph permutation and Gene permutation further prove that both graph 
permutation and gene permutation can reach good sensitivity and specificity, but graph 
permutation has higher specificity than gene permutation (Figure 2-5). The purpose of 
our method is to find active regulators in a certain condition, which means that specificity 
might be more important than sensitivity in our case. We will only focus on Graph 
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permutation results in the following. In contrast, the mean and ratio scoring functions 
seem to perform comparably, and a more in-depth analysis is needed.  
 
Figure 2-4. Effects of permutation on ranking regulators. ROC curves show that FDR 
calculated based on permutation can improve both sensitivity and specificity. Graph 
permutation is used here. Permutation and FDR correction can decrease false positives by 
filtering out regulators that have high scores but only regulate a small number of regulatees since 
a regulator can easily obtain a high score by chance if it only regulates a few regulatees. 
Similarly, permutation and FDR correction can increase true positives by recruiting regulators that 
have fair scores but can regulate a large number of regulatees. 
 
 
 
  
Figure 2-5. Comparison of graph permutation and gene permutation on two representative 
simulation data sets. (a) Simulation data set (r=0.5, p=50%). (b) Simulation data set (r=0.3, 
p=70%).  Scoring function “ratio” is used in both cases. Both permutation methods can reach 
good sensitivity and specificity. However, graph permutation reaches slightly better specificity in 
most cases. 
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2.3.2 Evaluation of scoring functions 
To understand the characteristics of the ratio and mean scoring functions, we focused 
on four datasets which differed in the strength of correlation r and the quantity of 
correlated regulatees p, namely, low/low (r=0.3; p=30%), low/high (r=0.3; p=80%), 
high/low (r=0.6; p=30%), high/high (r=0.6; p=80%). 
Figure 2-3b depicts receiver-operator characteristic (ROC) curves (see “Materials and 
Methods” for definitions) for the low/high and high/low datasets. The only substantial 
difference between the two functions becomes apparent in the case of few highly 
correlated regulatee pairs, in which the ratio function is able to reach higher true positive 
rate at the expense of a similar loss in true negative rate. Note that the ratio function is 
explicitly designed to address this case. In most other situations, the two functions are 
comparable with the mean function performing slightly better.  
2.3.3 Robustness to signal level and sample size 
Figure 2-6 shows the ROC curves under a variety of signal levels to demonstrate the 
ability of CSA to detect active regulators. In this instance, we use the ratio scoring 
function, but curves based on the mean function give similar results (data not shown). 
The curves demonstrate that CSA is able to pick out true active regulators embedded in 
the simulated data. For large sample sizes, the true positive and true negative rates 
were consistently high (>80%) for a wide range of score cutoffs. As expected, 
performance deteriorated with decreasing signal, but remained useful, even for very low 
levels of signal (Figure 2-6a). In contrast, Figure 2-6b depicts the situation with only 20 
patient samples. While for strong signals (p>70%), some regulators can be detected, 
weaker signals result in performance close to random. Together, this shows that our 
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causal network based on literature information is informative enough to enable recovery 
of embedded signals, given enough patient samples.  
 
Figure 2-6. Robustness of CSA with respect to different levels of signal (0%-90%) and 
sample size. ROC curves based on (a) 391 samples and, (b) 20 samples. CSA reaches high true 
positive rate and low false positive rate for different signal levels. 
  
2.3.4 Relevance of the causal network 
To further illustrate the relevance of the underlying causal network to provide informative 
active regulators, we generated a randomized version of the causal network with the 
same degree distribution (using the edge-switching procedure described in the 
“Materials and Methods”). Running CSA based on this randomized network against the 
simulated data and ovarian cancer data from TCGA resulted in ROC curves that were 
indistinguishable from random, indicating that the causal network is biologically 
informative (data not shown).  
2.3.5 Comparison to degree-based ranking 
Finally, we compare CSA’s results to an alternative approach that has been suggested 
as a general principle in many approaches to transcriptional network reconstruction, 
namely the prediction of key regulators or biomarkers based on their degree in the 
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inferred network [37, 63, 64]. Here, we use the same representative simulation data set 
(r=0.5; p=50%) as we used in the previous section. Implementing a ranking strategy 
based on each candidate regulator’s out-degree (number of targets they coherently 
regulate) gives an interesting baseline performance (Figure 2-7) that is clearly better 
than random. However, the ROC curves suggest also that the results based on our 
method are superior to a purely degree-based method. 
 
Figure 2-7. ROC curves of ratio score ranking and degree-based ranking. Red and blue 
ROC curves show ranking by ratio score and by out-degree (e.g. number of coherent expressed 
targets), respectively. The ROC curves suggest that degree-based ranking is better than random. 
However, ranking based on ratio score is superior to purely degree-based ranking. 
 
2.4 Results on clinical data 
To illustrate the utility of the CSA approach we describe here the results of comparing 
the directed perturbation experiments captured in the causal network to 3 different 
surveys of expression variation in 3 distinct disease and tissue settings – subcutaneous 
adipose tissue [51], ovarian cancer [50] and diffuse large B cell lymphoma [52]. 
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2.4.1 Experimental results I – Adipose tissue 
The first population dataset was subcutaneous adipose tissue from 673 individuals as 
described by Emilsson et al. [51], representing individuals from 3 generation families 
with a range of ages and degrees of obesity that was used to define loci affecting obesity 
in the Icelandic population. After matching transcripts measured in the adipose cohort to 
the causal network, the CSA method reported 246 of 1,762 (14%) regulators as 
potentially active at an FDR <0.05. This corresponds to 8,946 potential 
regulator:regulatee edges.  
These data can be summarized by counting the number of CSA significant regulatees 
for each regulator (Table S1 Appendix A). Amongst the top ranked regulators in adipose 
were some well-known metabolic targets, including PPARG (nc=275), PPARA (nc 
=218), Insulin (nc=136) and PPARGC1A (nc=105). The top hit as judged by the size of 
significant regulatees was MYC (nc=391) which has been implicated in adipogenesis 
[65]. It is interesting to note that the well-known transcription factor, MYC, was not co-
expressed with its regulatees in the adipose tissue dataset (average correlation 
coefficient=0.1161), but a subset of its regulatees were coherently expressed. This 
observation supported our hypothesis. An additional top hit was, NFE2L2 (also known as 
NRF2, nc =285), a master regulator of anti-oxidant response that has been implicated in 
many disease processes and in adipogenesis and obesity specifically [66].  
Adipose tissue is composed of adipocytes and a stromal fraction including 
macrophages. Given this knowledge, we asked if CSA provided evidence for these sub-
populations of cells. Perilipin (PLIN1) is a protein uniquely expressed in adipocytes (see 
Figure 2-8a and 2-8b) where it coats the surface of intracellular lipid droplets and 
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protects them from degradation by lipases. CSA identifies 37 PLIN1 regulatees as 
cohesive in adipose tissue consistent with it being a significant regulator in human 
adipose tissue. A major conclusion of the adipose tissue study used here was that 
macrophages, as observed by macrophage-specific transcripts, are identified as causal 
drivers of obesity in humans [51] and mouse [67]. Consistent with this CSA finds a 
number of macrophage specific genes as active drivers including the chemokine 
receptor CCR1 (Figure 2-8c and 2-8d). One of the ligands of CCR1, RANTES is 
reported to be secreted by adipocytes and recruits macrophages to fat depots [68]. 
CCR1 appears as both a target of other regulators and as a regulator of downstream 
transcripts as judged by CSA (see Figure 2-8c). Furthermore the regulators of CCR1 
were also found to be connected to each other consistent with a web of regulatory 
interactions affecting CCR1 and its downstream targets in macrophages in human 
adipose tissue. 
Given the relative ease of experimentation, it is not surprising that many experiments 
reported in the literature were performed in cultured cell models. In this setting there is 
always a question of the relevance of the results to human populations. CSA potentially 
provides a data-driven way to assess this by testing whether any perturbation signature 
(or fraction of a signature) is significantly cohesive in a disease population. Interestingly, 
CSA identified many cell culture derived signatures as being relevant to the 
subcutaneous adipose tissue of humans (more than 53% individual references using 
cells in culture covered 47% regulator:regulatee edges). This included, for example, 88 
of 254 regulatees for the classic adipose regulator PPARG and 68 of 116 insulin 
regulatees. 
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Figure 2-8. (a) Gene expression of PLIN1 in different tissues. (b) PLIN1 and some of its 
downstream regulatee. (c) CCR1 and its upstream regulators (red nodes) and downstream 
regulatees (blue nodes). (d) Gene expression of CCR1 in different tissues. (a) Gene 
expression of PLIN1 in different tissues. (b) PLIN1 and some of its downstream regulatees. (c) 
CCR1 and its upstream regulators (red nodes) and downstream regulatees (blue nodes). (d) 
Gene expression of CCR1 in different tissues. (a) and (d) are from BioGPS, which show that 
PLIN1 and CCR1 are uniquely expressed in adipocytes and Macrophages, respectively. (b) 
PLIN1 regulates 37 regulatees in adipose tissue. (c) CCR1 is regulated by numerous regulators 
in the causal network. CSA identified 14 potential active regulators of CCR1 in the adipose tissue 
(red). CCR1 is a regulator that can regulate several downstream regulatees (blue); at the same 
time, CCR1 is also regulated by many other regulators. These regulators regulate each other and 
also CCR1's regulatees.  
 
2.4.2 Experimental results II – Serous ovarian cancer 
The CSA method was also assessed against a collection of expression profiles from 
almost 400 human serous ovarian cancers available through TCGA project [50]. After 
matching transcripts measured in the ovarian cohort with the causal network, it was 
found that 357 of 1,398 (26%) regulators had an FDR <0.05 in the CSA analysis (see 
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Table S2 Appendix B). This identifies 12,860 potential regulator:regulatee edges as 
active in this cohort. 
As before, the potential regulators can be ranked by the number of regulatees that pass 
the cutoff. Top ranked regulators include genes implicated in many cancers (see Table 
S2 Appendix B) such as TGFB1 (nc=520), IFNG (nc=485), FGF2 (nc=241), MYCN 
(nc=219) and VEGFA (nc=183). Again, we observed that another well-known 
transcription factor, MYCN, was weakly correlated with its regulatees (average 
correlation coefficient = 0.1015), but it had a subset of coherent regulatees and were 
identified by CSA as active in ovarian cancer dataset. CSA also identifies numerous 
potential drivers of various cyclins which are known to drive the cell cycle and be 
aberrantly regulated in cancer (see Figure 2-9a). Among 603 regulators that regulate 
cyclins in the causal network, CSA identified 77 as active in the serous ovarian cancer. 
As with the CCR1 example extensive cross-regulation of cyclin regulators was predicted, 
suggesting the presence of a complex network of causal interactions upstream of cyclins 
in ovarian cancers revealed by CSA. The derivation of the higher-order structure is non-
obvious given the literature examples alone, but readily emerges from the CSA analysis 
as relevant in this context. Using the ranking by the number of edges testing significant 
in CSA, TNF was found to have 657 regulatees (reactive to TNF) and 153 regulators 
(causal regulators of TNF) in this cohort. High levels of secreted TNF protein (ranked 
first by CSA) were reported to cause high levels of the proteins IL6, MIF, CCL2, 
CXCL12, VEGFA, also secreted in ovarian cancer cell lines [69]. Intriguingly, these 
genes in the CSA analysis of the ovarian cancer cohort were also found to have many 
regulatees (304, 0, 13, 0, 183, respectively) and/or regulators (158, 5, 64, 18, 26, 
respectively), and directly and reciprocally regulate each other (see Figure 2-9b). As 
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reported by Kulbe et al. [69], knockdown of TNF in cells with high TNF results in failure 
to form tumors in mice. The interpretation of such established cell line models of cancer 
can be difficult. The CSA analysis however indicates that the basic regulatory findings of 
this work were replicated by CSA and found to be the most dominant feature in 
approximately 400 ovarian clinical cancer samples. Together, these findings may identify 
a critical driver of ovarian tumor growth in vivo. 
 
Figure 2-9. (a) Regulators regulate cyclins in serous ovarian cancer. (b) Hypothesis 
regulatory model of secreted proteins in serous ovarian cancer. (a) Cyclins have 603 
regulators in the causal network. CSA identified 358 potential active regulators in serous ovarian 
cancer; 77 of 358 regulators were found to regulate cyclins. Regulators (red nodes) regulated 
cyclins (blue nodes) and also regulated each other, which implies that these regulators work 
cooperatively to regulate cyclins. (b) Secreted proteins TNF, IL6, VEGFA and CCL2 were 
identified as regulators (red nodes) in serous ovarian cancer by CSA. They regulated each other 
and two other secreted proteins, MIF and CXCL12 (green nodes). TNF, IL6, VEGFA and CCL2 
are also used as therapeutic targets of several different kinds of cancers [70–73].  
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2.4.3 Experimental results III – DLBCL 
The final example is a study of diffuse large B-cell lymphoma (DLBCL) in which 
expression profiles of 2 patient populations who subsequently received different 
treatments were examined for signatures that predict the clinical course of the disease 
[52]. For the purposes of this analysis the subsequent treatments are not relevant. The 
first cohort (CHOP) included 181 samples and the second cohort (R-CHOP) included 
233 samples. As described in [52], 3 signatures were derived in a multivariate analysis 
that predict survival in the 2 cohorts. The Germinal Center B-cell signatures contained 
37 genes, the Stromal-1 signature contained 264 genes and the Stromal-2 signature 
contained 61 genes. CSA analysis was applied to each of the cohorts and potentially 
active regulators identified that pass the FDR cut-off (218 and 220 of 1780 significant 
hits for CHOP and R-CHOP, respectively (see Table S3 Appendix C). Using these 
significant hits we then asked if any of the regulators regulated genes involved in the 3 
predictive signatures (Germinal Center B-cell, Stromal-1 or Stromal-2). Interestingly, 
although the Stromal-1, and -2 signatures were found by a multivariate analysis, 
suggesting they are independent, CSA analysis identifies genes that can regulate both 
signatures jointly. Among the 131 regulators that regulate at least one gene in either the 
Stromal-1 or -2 signatures, 53 (40%) regulate genes in both cohorts. Furthermore, we 
calculated the significance of the enrichment of each regulator’s regulatees for overlap 
with the 3 predictive signatures by Fisher’s exact test. Significant enrichments for the two 
Stromal signatures were found (see Table 2-1). Figure 2-10 shows the regulators 
enriched for Stromal-1 and -2 signatures in the CHOP and R-CHOP cohorts and their 
target genes in all three signatures. 11 regulators were found enriched for Stromal-2 
signature in both cohorts. Surprisingly, all of these 11 regulators are also enriched for 
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Stromal-1 signature, indicating that it is possible the 2 signatures arise because of the 
same regulator(s). 
The candidate regulators can be ranked by the number of predictive signature genes 
they regulate (limiting to those enriched for the signatures). This results in the 
identification of some very familiar drivers of many cancers including MYC, MYCN and 
CCND1 (see Table 2-1).  
Table 2-1. Top 15 regulators found in CHOP and R-CHOP cohorts. 
 
No. of 
Regulateesa 
Germinal  
Center B cellb Stromal-1
c
 Stromal-2d 
Regulator CHOP R-CHOP CHOP R-CHOP CHOP R-CHOP CHOP R-CHOP 
TGFB1 723 632 0.2379 0.3081 1.36E-12 2.30E-14 0.0003 7.36E-05 
IFNG 624 553 0.5868 0.6600 0.0041 0.0006 0.1928 0.1008 
MYC 439 410 0.1870 0.2094 0.0013 0.0005 0.1427 0.0673 
IL6 370 317 0.5962 0.6678 0.0281 0.0497 0.2135 0.0854 
MYCN 272 248 0.3566 0.3908 8.22E-06 7.20E-06 0.4979 0.5463 
ERBB2 253 219 0.3731 0.3666 7.50E-07 2.79E-07 0.0149 0.0088 
IFNB1 251 233 0.3864 0.4139 0.1869 0.1256 0.4674 0.4826 
IL10 249 221 0.3727 0.3672 0.0950 0.0543 0.1307 0.1080 
CDKN1A 234 224 0.3704 0.3680 0.0953 0.0554 0.4817 0.2436 
F2 233 212 0.4139 0.4484 0.0009 0.000372 0.0409 0.0317 
IL2 205 188 0.4605 0.4912 0.3236 0.4066 0.6388 0.6769 
CCND1 204 184 0.4622 0.4987 7.86E-05 2.38E-05 0.0013 0.000777 
VEGFA 189 170 0.4894 0.5259 3.27E-05 3.60E-05 1.86E-06 7.91E-06 
MAPK1 183 166 0.5006 0.5340 0.0063 0.003266 0.3192 0.3550 
TNFSF11 166 150 0.1038 0.0898 0.5435 0.6276 0.1905 0.1714 
anumber of cohesive regulatees.  
b,c,dthe enrichment p-values of Germinal Center B cell, Stromal-1 and Stromal-2 signatures in CHOP and R-CHOP 
groups. 
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Figure 2-10. Regulators enriched for Stromal-1 and Stromal-2 signatures. Red nodes are 
regulators. Yellow nodes are genes in Germinal center B-cell signature. Blue nodes are genes in 
Stromal-1 signatures. Green nodes are genes in Stromal-2 signatures. We did not find any 
regulator enriched for Germinal Center B-cell signature works in both cohorts. Instead, CSA 
identified 41 and 11 regulators enriched for Stromal-1 and -2 signatures in both cohorts. 
Furthermore, the regulatory model showed that the majority of genes in Stromal-2 signature are 
regulated by regulators that also regulate Stromal-1 signature. 
 
 
2.4.4 Results on clinical data with the public causal network 
Selventa Inc. has recently launched an initiative to provide access to a significant 
amount of causal information to academic researchers. We performed CSA on the 
ovarian cancer dataset with the public causal network released by Selventa Inc. The 
result suggested that 121 of 170 regulators reported by CSA (FDR < 0.05) with the 
public causal network were found in our previous result (Table S4 Appendix D). 
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Compared with 358 causal regulators identified by using the complete causal network, 
CSA can recover about 1/3 of the regulators in the ovarian cancer dataset. The results 
suggested that CSA works well with the public causal network although it does not report 
as many causal regulators as with the complete causal network. 
 
2.5 Conclusions 
The advent of inexpensive high-throughput transcriptomics measurement techniques 
has enabled the characterization of cell lines, animal models, and, more recently, 
cohorts of clinical patients on a molecular level. A crucial research question in such 
studies (e.g. in ovarian cancer patients) is the identification of causal regulators of the 
observed transcript changes. In this study, we sought to develop a method, Correlation 
Set Analysis (CSA), to identify directed perturbation experiments relevant to a disease 
population of interest in an unbiased data-driven manner. The method relies on the 
hypothesis that regulatees of a regulator active in a population will be significantly 
correlated to each other across the population. As described the CSA method was 
developed and evaluated on simulated data where it found to be quite sensitive in 
identifying known regulator effects.  
To test the method and illustrate its uses, we present the results of CSA analysis in three 
disease settings, where in each case known key regulators and as yet un-described 
regulators were found. In the regulatory networks of CCR1 in adipose tissue and cyclins 
in serous ovarian cancer, we observed that upstream regulators of CCR1 and cyclins not 
only regulated CCR1 and cyclins but also regulated each other. For example, both 
TNSF12 and CCL5 regulate CCR1 and CCR1's downstream regulatee, MMP1, but 
CCL5 is also regulated by TNSF12 at the same time. Also in the DLBCL dataset, we 
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found that of 11 regulators enriched for Stromal-2 signature in both CHOP and RCHOP 
cohorts were also enriched for Stromal-1 signature. This finding implies that Stromal-1 
and -2 signatures are actually regulated by the same regulators. These examples 
indicate that CSA is able to bring together isolated regulatory relationships into higher 
order regulatory networks, and thereby adding new knowledge and insights. 
Based on this we propose that CSA has four key advantages. Firstly, it provides a 
simple data driven way to connect population data with the many directed perturbation 
experiments reported in the literature. Secondly, CSA identifies plausible changes in 
regulators at the protein level, since we do not require correlation between regulator and 
regulatees. A third advantage of this approach is that the results can be simply ranked 
providing the user with an intuitive way to prioritize any follow up investigation. Finally, 
the regulatory relationships inferred by CSA were found in all cases to form a contiguous 
network, with many cases of regulators that were also regulatees of upstream 
regulators. In other words CSA provides a glimpse of the true underlying higher order 
structure of biological systems which can be systematically tested for causal effects on 
disease progression. 
In addition to the advantages it is worthwhile noting that there are some limitations to 
CSA that stem from its reliance on the literature-derived causal network. Clearly, the 
relationships identified are limited to the causal network used. With the continued 
expansion of our understanding of regulatory relations, the accuracy of CSA should 
improve with time. Another possible limitation is in cases where overlapping sets of 
regulatees are controlled by distinct regulators. In this case, CSA will not be able to 
distinguish between the regulators resulting in an increased false positive rate. One 
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possible solution for this problem is to cluster regulators by the similarity of their 
respective regulatee sets. In our experience, however, the overlap between regulatee 
sets is still sufficiently small to allow for meaningful inference. This is supported by the 
excellent performance of CSA on simulated data. 
As we mentioned before, the causal network in its original form contains not only genes 
and proteins, but also chemical compounds and environmental factors. Since our 
approach does not restrict regulators to genes on the microarray, such entities can 
appear as candidate regulators, though we did not report them in this work. Hypotheses 
based on compounds might be useful for assessing environmental factors driving 
disease progression or for supporting drug repositioning efforts. 
In the future we plan to apply the CSA method to large scale compendia of gene 
expression sets to understand patterns of active regulation across a span of phenotypes. 
Given the promising performance of CSA when recovering embedded regulators as well 
as providing insights for biological datasets, we believe that it will greatly enhance our 
understanding of general and specific mechanisms driving disease and other relevant 
phenotypes. 
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Chapter 3. Identification of driver modules in cancer by using a weighted 
functional linkage network 
3.1 Introduction 
The number of causal molecular alterations that have been identified in cancer cells is 
far smaller than the total number of identified alterations; i.e. large numbers of alterations 
occur sporadically, and display in a relatively small fraction of cancer cells. This large 
background of mutations and the paucity of prior evidence for causality make systematic 
experimental investigation impractical and render reliable statistical identification of 
drivers difficult. 
Driver identification has been approached in a number of ways. The most widely used 
approaches attempt to identify single nucleotide polymorphisms (SNPs) or copy number 
variants (CNVs) having abnormal occurrence frequencies in cancer cells, which are 
statistically significant [13, 14]. The assumption underlying this approach is that a 
mutation that drives cancer will confer a growth advantage on the cancer cell, and the 
mutation will therefore become common. Other approaches exploit the idea that non-
synonymous mutations are more likely than synonymous mutations to be potential 
drivers [18, 74].  
More recent methods focus on pathways--such as proliferation, apoptosis, angiogenesis, 
and metastasis—which can mediate transformation [5]. Since a pathway can in principle 
be altered by a mutation in any of its genes, the likelihood of finding the same aberrant 
gene across a set of samples is far smaller than that of finding the same aberrant 
pathway. Some computational methods therefore focus on the identification of 
processes that distinguish normal from cancer phenotypes [21, 22]. Many traits, 
however--including cancers--are not readily distinguished by sets of genes represented 
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by traditional pathways, but reflect crosstalk between and among subsets of genes in 
different pathways, or previously ungrouped sets of genes. This suggests that methods 
aimed at identifying phenotypic distinctions should include correlations between genes. 
For example, Cerami et al. identified drivers in glioblastoma by finding modules in a 
literature curated network [75]. Another study by Torkamani et al. constructed 
coexpression networks in cancers and identified modules enriched in somatic mutations 
in glioblastoma, breast and colon cancer [76].  
Our approach also focuses on functional modules of genes rather than individual genes. 
In particular we develop and use a novel approach, Functional Linkage Network 
Partitioning (FLNP), to find breast and ovarian cancer specific functional gene modules 
that are highly enriched in known oncogenes. The basic idea is simple. Starting with a 
minimum boundary surrounding a set of known cancer genes that are connected on an 
evidence weighted functional linkage network, we move genes in and out of the 
boundary until we reach a module that maximizes a target function, which we take to be 
the difference between the average intragenic and intergenic weights (Methods). Since 
the modules consist of genes that have strong functional relations, we classify all other 
genes in the module as candidate drivers, provided enough is known about their function 
to plausibly implicate them in processes associated with transformation. 
3.2 Materials and methods 
Previous studies have shown that proteins involved in the same disease tend to be 
functionally related, or serve a common process [77, 78]. With that in mind we have 
developed an algorithm FLNP that detects sets of genes that are in the functional 
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neighborhood of well-known drivers of cancer, where functional neighborhood is defined 
on our functional linkage network (FLN), as we now explain. 
3.2.1 Functional linkage network 
The FLN consists of genes (nodes) connected by evidence weighted links [79, 80]. A 
particular network topology is realized by choosing a threshold for accepting a link; if the 
link between two nearest neighbor nodes exceeds the threshold, the link is realized, 
otherwise it is suppressed. FLNs have been used successfully in many contexts, 
including gene and protein annotation [81–83], genotype-phenotype association for 
diseases and disorders, [79, 84–86] and the identification of functional modules [87]. In 
the FLN we used in this study, the link weights were established, by integrating 16 
genomic features using a Naïve Bayesian classifier [79]. Unlike protein-protein 
interaction networks or regulatory networks, the FLN topology reflects functional 
similarity. Previous studies have shown that FLNs can strongly improve both sensitivity 
and specificity in identification of candidate disease genes [79, 88]. 
3.2.2 Seed selection 
Our algorithm for finding a module starts by choosing a seed set: a small number of 
known oncogenes associated with the cancer of interest. Many databases have 
collected mutations in a variety of diseases, including cancers. The Online Mendelian 
Inheritance in Man (OMIM) database provides comprehensive and highly reliable 
contexts of human genes and genetic phenotypes [89]. OMIM covers 14,013 genes and 
7,296 genetic phenotypes, including 91 major types of cancers. The Catalogue Of 
Somatic Mutations In Cancer (COSMIC) is another human curated database which 
collects somatic mutations in human cancers from literatures [90]. Together OMIM and 
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COSMIC provide 651 validated oncogenes for about 90 types of cancers (as June 
2012); those oncogenes are treated as drivers in this study. 
The Genetic Association Database (GAD) extracts candidate genes associated with 
complex diseases from published papers based on genome-wide association studies 
(GWAS) [91]. Although GWAS can provide evidence that a gene is disease associated, 
the association is less reliable than it is for OMIM and COSMIC genes, owing to 
insensitivity to rare single nucleotide polymorphisms (SNPs), false positives caused by 
multiple testing, and substantial variation between studies [92, 93].  
We select known mutated genes from OMIM, and require that a continuous pathway on 
the FLN must exist between oncogenes if they are to be considered members of the 
seed. 
3.2.3 Identification of functional disease module 
A well-accepted and intuitive definition of a module in a network is a group of densely 
connected vertices, which have many edges between vertices within the group but with 
only a smaller number of edges between vertices of different groups [94]. In a biological 
network, we extend the definition of a module from a set of densely connected vertices 
to a set of strongly functional related genes. Namely, genes are grouped into a module 
based on the strength of functional connections rather than number of edges between 
them.  The function may refer to a biological process, molecular function or a phenotype 
[5]. Therefore, a functional linkage network which represents the functional correlations 
between genes is a good way for identifying functional modules.  
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We take as an ansatz that genes interior to a module have a higher functional correlation 
with one another, than they have with exterior genes. Specifically, for a module }{kM =
, consisting of k genes, the set of neighboring exterior genes )(kNG , we define a 
modularity score, dS  as 
∑∑ ∈∈−∈∈=
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where ω  is the weighted adjacency matrix, p  is total number of edges within the 
module M , and q  is the total number of edges between module M  and the 
neighborhood community )(kNG . The element ji ,ω in the weighted adjacency matrix ω  
represents the weight of the edge between genes i  and j . 
The objective is to maximize the target function, dS , subject to the constraint that it must 
be greater than θ . θ  is the threshold for defining a module, which we take to be zero for 
maximum  sensitivity. 
Modules can of course be defined in a number of different ways. For example, KEGG 
pathways are also modules [95]. If our definition is to be useful for discovery, we’d 
expect our modules to include those obtained using other definitions. We therefore 
calculated scores for KEGG pathways and GO terms.  
KEGG. We found that 242 of 245 (98.8%) KEGG pathways have a modularity score 
greater than 0, with an average dS  of 1.27. 
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Gene Ontology (GO). We classified GO into 12 coverage levels as defined in our 
previous work [96]. Coverage increases as level decreases; i.e. terms become 
increasingly specific as level increases.  
 
Figure 3-1. Distribution of modularity score dS  of GO terms. 
 
Figure 3-1 shows the distribution of  for GO terms (having at least 2 genes) at 
different levels. The results indicate that 8,833 of 9,865 (89.5%) GO terms in the 
biological process branch, 2,530 of 2,649 (95.5%) GO terms in molecular function 
branch and 1,070 of 1,147 (93.3%) GO terms in cellular component branch have greater 
dS
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than 0. In addition,  increases with specificity, especially GO terms in cellular 
component branch. This implies that the compartmentalization of modules may affect the 
modularity score. Genes or proteins that are active in the same part of the cell tend to 
have higher functional correlations. Although we did not consider the 
compartmentalization of modules in this study, it is worth to take this into account in the 
future work. 
3.2.4 Implementation of the algorithm  
FLNP starts by choosing a small number of connected seed genes on the FLN without 
applying any cutoff on edge weight. In each cycle, genes in )(kNG  are moved 
sequentially to the interior, and dS  is computed. At the end of the cycle, we retain in the 
interior the gene that has increased the score the most. The algorithm performs a greedy 
search and stops when no gene in )(kNG  can be found to increase the modularity score 
(Figure 3-2). Because the algorithm does not guarantee a global optimum, it is possible 
that the removal of some genes from the final module will increase the score. To 
determine how large this effect might be, we sequentially removed each gene and 
recomputed the modularity score. For breast cancer, there is no gene whose removal 
increases the dS  by more than 0.1. The removal of 22 of 81 genes in the breast cancer 
module will slightly increase dS  by 0.01 to 0.02. For ovarian cancer, none of the genes 
in the module decreases dS  by more than 0.1. The removal of 20 of 47 genes in the 
ovarian cancer module will slightly increase dS  by 0.01 to 0.05. Considering the inherent 
approximations in the procedure used to obtain the weights, these differences are 
dS
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considered to be within the margin of error of the method. An FLNP interface is available 
at http://visant.bu.edu/FLNP.  
 
Figure 3-2. Overview of the algorithm. 
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3.2.5 Statistical significance 
We are interested in both modularity and driver context, and use a permutation test to 
evaluate the significance of each. To assess the significance of the modularity score we 
used a background distribution of modules based on randomly chosen seeds, with the 
same number of seed genes as the unique oncogene module. The procedure is 
repeated 2000 times.  
To assess the biological significance of the identified oncogene module we estimate the 
frequency with which the number of oncogenes found in our oncogene module, would be 
found in a set of random modules. In each of 1000 iterations, we randomly selected the 
same number of seed genes used in our oncogene module, excluding oncogenes, and 
then use the algorithm described above to obtain a module. 
3.3 Results and discussion  
3.3.1 Case study I – Breast cancer 
3.3.1.1 Seed selection 
OMIM lists mutations in 22 genes that are possible contributors to breast cancer. A gene 
may have one or more mutations in breast cancer, but for the purpose of this paper, we 
are concerned only with the binary classification of the gene. We excluded uncertain 
mutations (entry with braces, “{}”, in OMIM, which represents mutations that are highly 
possible disease related mutations but yet to be confirmed) leaving 11 genes that are 
confirmed to drive breast cancer. After removing singletons (genes that do not connect 
to any other genes in the seed set), 9 genes remained, and we used all 9 as our seed 
set (Table 3-1). With θ  set to 0.1, FLNP uncovered a breast cancer module with 81 
genes (Table S1 Appendix E). A sampling calculation (Methods) indicates that the value 
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attained by target function is well above that of random gene modules of comparable 
size (p-value = 0.017). 
Table 3-1. Seeds set of breast cancer 
Gene symbol Entrez  
Gene ID 
Aberration References 
PPM1D 8493 Amplification Li et al. (2002) 
TP53 7157 Mutation (pro151-to-thr and 
pro151-to-ser) 
Carrere et al. (1993), 
Chen et al. (1991) 
BRIP1 83990 Somatic mutation (pro47-to-ala 
and met299-to-ile) 
Cantor et al. (2001) 
AKT1 207 Somatic mutation (glu17-to-lys) Carpten et al. (2007) 
KRAS 3845 Somatic mutation (gly13-to-asp) Kozma et al. (1987) 
PIK3CA 5290 Somatic mutation (his1047-to-arg, 
his1047-to-leu and glu545-to-lys) 
Campbell et al. (2004) 
RB1CC1 9821 Deletion of exons 3-24 and exons 
9-23 
Chano et al. (2002) 
SLC22A18 5002 gain of imprinting Gallagher et al. (2006) 
TSG101 7251 loss of heterozygosity Li et al. (1997) 
 
3.3.1.2 KEGG pathways that intersect the module  
Pathways that contribute to altered physiology in cancer cells occur at an unusually high 
rate in our module. In particular we used DAVID [97, 98] to evaluate the overlap between 
KEGG pathways and the breast cancer module and found nine such KEGG pathways 
(excluding pathways specifically labeled with the term cancer; e.g. the “prostate cancer” 
pathway) shared a certain fraction of their genes with those in the breast cancer module 
with false discovery rate (FDR) smaller than 0.05. These included the VEGF signaling 
pathway (angiogenesis); the Adherens junction, Focal adhesion, and regulation of actin 
cytoskeleton pathways (metastasis); the erbB signaling, GnRH signaling, MAP Kinase 
signaling and Progesterone-mediated oocyte maturation pathways (growth); and the 
apoptosis pathway.  Table S2 in Appendix F lists genes that are in the breast cancer 
module for each cancer-related pathway and the p-value and FDR of each pathway. 
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3.3.1.3 Oncogene enrichment 
Among the 81 genes in the breast cancer module, 72 were not members of the seed set. 
These can be placed into four categories. (a) Thirty are known oncogenes found in 
COSMIC and OMIM (Boxes in Figure 3-3). The estimated probability for chance 
occurrence is smaller than 0.001, which means none of the 1000 random modules has 
higher concentration of oncogenes than the breast cancer module. This was obtained by 
using the statistical test we described in the method section. Of the (72 - 30 =) 42 genes 
which have not been previously identified with breast cancer, we estimate that 
(42×39/81 =) 20 will be drivers. This point estimate is likely to be conservative since 
there is independent evidence (discussed below) supporting driver status. (b) Four are in 
the Genome Association Database (GAD) and implicated by genome wide association 
studies (GWAS). GWAS and our findings are independent and therefore mutually 
supportive. (c) A separate analysis performed by our collaborator Gabriela Alexis 
(unpublished data) indicates that 6 of the remaining 38 have a significantly high non-
silent mutation or amplification/deletion rate across 781 breast cancer samples in The 
Cancer Genome Atlas (TCGA) with an FDR < 0.05. Here, too, our results and those 
obtained by analyzing TCGA are independent, and therefore mutually confirmatory. 
(d) For the remaining 32 genes there is no evidence for a causal role in initiation or 
progression of cancer, although 12 are in one or another of the 9 cancer-related 
pathways that overlap the module. 
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Figure 3-3. Breast cancer module. Boxes are known oncogenes from OMIM and COSMIC. The 
red nodes are breast cancer drivers obtained from OMIM, which were used as seeds; blue nodes 
are genes with high mutation frequencies in the TCGA breast cancer population; green nodes are 
the remaining genes in the breast cancer module. Edges between genes are from the functional 
linkage network, which represents the functional relations between genes; edge thickness reflects 
the strength of functional relation.  
 
3.3.1.4 Comparison with other methods 
We compared our algorithm with NetBox [75] and with an FLN based method previously 
developed in our Lab [79]. NetBox identifies disease modules from an integrated 
literature curated network by starting from a group of altered genes. Using our seed set 
as the input into NetBox resulted in a breast cancer network with 92 genes, 85 of which 
were not members of the seed set. Of the 85, 25 (29.4%) were known oncogenes as 
indicated by OMIM and COSMIC. The breast cancer module identified by FNLP was 
slightly more enriched in oncogenes (30 of 72, 41.7%). More importantly, to the extent 
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that reproducibility is an important condition for driver candidacy, we note that 23 genes 
were reported by both methods (Table 3-2). 
We used DAVID to find pathways that are enriched in candidate breast cancer drivers 
identified by NetBox, and found that the nine cancer-related pathways identified by 
FLNP were also enriched in NetBox (FDR<  0.05). 
The third method (historically, the first)  [79]  is a simple and direct FLN (DFLN) based 
prioritization; viz., genes are ranked by the sum of the weights of their links to 
neighboring oncogenes. DFLN is not module based, and provides no guidance on where 
to threshold for candidacy. In order to compare results we picked the top 72 genes 
determined by DFLN, the number in our breast cancer module. The results show that 
FLNP performance is similar to that of DFLN, but with a smaller seed set (Table 3-2). 
Of the 12 genes identified by all three methods, 6 are oncogenes - DAXX, EP300, 
MDM2, RAF1, BCL2 and SRC. For the other six genes that are not listed as oncogenes 
by either OMIM or COSMIC, there is independent evidence supporting the possibility 
that they are breast cancer drivers. For VEGFA the evidence comes from GWAS [99]. A 
separate analysis performed by our collaborator Gabriela Alexis (unpublished data) 
indicates that CHEK1 and NFKBIA have a significantly high non-silent mutation or 
amplification/deletion rate across all samples in the TCGA breast cancer cohort (FDR < 
0.05). Finally, GSK3B and PTK2 have been implicated in breast cancer related 
pathways, e.g. the ErbB signaling pathway, focal adhesion pathway and VEGF signaling 
pathway [100–102]. 
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Table 3-2. Number of oncogenes, GAD listed genes and genes with high alteration rate in 
TCGA breast cancer samples identified by FLNP (A), NetBox (B) and DFLN (C). 
 FLNP (A) NetBox (B) DFLN (C) (A,B) (A,C)  (A,B,C) 
Module size 
(excluding seeds) 
72 85 72 23 18 12 
Known 
oncogenes 30 (41.7%) 25 (29.4%) 35 (48.6%) 12 11 6 
GAD 10 (13.9%) 11 (12.9%) 12 (16.7%) 5 4 3 
TCGA 19 (26.4%) 16 (18.8%) 16 (22%) 6 4 2 
 
Our results significantly overlap the recent findings Stephens et al. who constructed a 
landscape of breast cancer genes from 100 tumors, and identified 40 genes possessing 
potential driver mutations [103]. 12 of 40 are in our breast cancer module, including (a) 
genes previously implicated in breast cancer development, e.g. TP53, AKT1, BRCA1, 
RB1 and PIK3CA, (b) novel genes with driver mutations, e.g. AKT2 and CDKN1B, and 
(c) likely drivers found in other cancer types, e.g. KRAS and MAP2K4. Notably, all 12 
genes are oncogenes associated with least one kind of cancer. The results are 
summarized in Table 3-3 and Figure 3-3. 
Table 3-3. Breast cancer module genes with high mutation rate or amplification/deletion in 
TCGA breast cancer population and the study by Stephens et al. 
Gene Function Abnormal type in TCGA breast cancer population FDR Stephens et al. 
CDKN1B Tumor 
suppressor Deletion 0.007795 
Truncation/ 
Missense  
Novel breast 
cancer driver 
CDKN2A Tumor 
suppressor Deletion 5.43E-27  
CHEK1 Protein kinase Deletion 5.17E-15  
AKT1* Oncogene Missense 1.14E-08 Known breast 
cancer driver 
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FOXO3 Tumor 
suppressor Deletion 6.70E-07  
MTOR Protein kinase Deletion 1.32E-24  
IKBKB Protein kinase Amplification 1.66E-27  
NFKBIA Tumor 
suppressor Amplification 0.01066  
PAK1 Oncogene Amplification 5.89E-58  
WWOX Tumor 
suppressor Deletion 3.62E-06  
PIK3CA* Oncogene Amplification 2.32E-05 Known breast 
cancer driver 
PIK3R1 Enzyme INDEL/Missense Deletion 
1.13E-10 
(Mutation) 
2.31E-06 
(CNV) 
RB1 Tumor 
suppressor Deletion 1.22E-22 
Known breast 
cancer driver 
RPS6KB1 Protein kinase Amplification 1.27E-56  
MAP2K4 Tumor 
suppressor 
INDEL/Missense/Nonsense 
Deletion 
1.13E-10 
(Mutation) 
6.17E-16 
(CNV) 
Likely driver  
BRCA1 Tumor 
suppressor Deletion 0.000214 
Known breast 
cancer driver 
AKT2 Oncogene   
Missense 
Novel breast 
cancer driver 
TP53* Tumor 
suppressor Missense 
<8.64e-12 
 
Known breast 
cancer driver 
KRAS* Oncogene   Likely driver  
*seed genes 
 
In order to more clearly see relations between genes, we remove weak links (functional 
linkage weight < 0.2) from the breast cancer module. This results in two major sub-
groups (Figure 3-3), one centered on TP53 and the other centered on AKT1. The AKT 
centered sub-group includes genes in the MAPK signaling pathway and the PI3K-AKT 
signaling pathway. It is connected to TP53 via a series of mutated genes in breast 
cancer (blue boxes). Previous studies also proved that the MAPK signaling pathway and 
the PI3K-AKT signaling pathway is critical to the development of breast cancer and is a 
possible therapeutic target [104–106]. These subgroups are consistent with common 
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breast cancer subtypes. In particular, the two luminal subtypes are dominated by PI3K 
oncogene mutations, whereas mutations in P53 and in the MAPK pathway are widely 
distributed across samples of basal-like tissue. 
We also found genes that have not yet been reported as drivers in large scale studies, 
but for which there is suggestive evidence of association with breast cancer progression. 
For example, PAK1 has a high mutation rate in the TCGA breast cancer population, 
though it is not reported as a driver of any cancer in either OMIM or COSMIC. PAK1 is 
linked to AKT1, RAF1 and some MAP kinases. A recent study carried out by Shrestha et 
al. indicates that PAK1 is a breast cancer oncogene and may cause a predisposition to 
breast cancer by activating MAPK and MET signaling pathway [104].  
Our results included not only known or possible drivers but also novel candidates. BRAF 
encodes a serine/threonine protein kinase that helps regulate the MAPK signaling 
pathway. MAPK signaling is related to several important cellular functions, including 
differentiation and proliferation, and plays an important role in various types of cancer, 
including breast cancer. Mutations in BRAF are known to drive melanoma, non-small-
cell lung cancer, adenocarcinoma and colorectal cancer [107–110], possibly by 
disrupting phosphorylation of MEK and the activation of ERK in the MAPK signaling 
pathway[111]. Although it has not been previously classified as a driver of breast cancer 
in either OMIM or COSMIC, our results, and the known biology of BRAF, as well as its 
implication in other cancers, taken collectively strongly suggest that it drives breast 
cancer. 
In conclusion, we found that the breast cancer module contains many well-known 
drivers, and therefore expect that many of the remaining genes are good candidates for 
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drivers. Consequently for this 81 gene module, we recover 30 known oncogenes, and 
have reasonable prima fascia evidence for 11 genes that have not previously been 
classified as cancer drivers.  
3.3.2 Case study II – Ovarian cancer 
3.3.2.1 Seed selection 
We collected 7 genes that are known to be mutated in ovarian cancer from OMIM. One 
of them was a singlet, not connected to any of the others, and was therefore removed 
from the seed set (Table 3-4). With θ  set to 0, FLNP converged on a 58 gene module 
(Figure 3-4 and Table S3 Appendix G). As shown in Methods, the value obtained by the 
target function is well above that associated with random modules (p-value = 0.0035).  
3.3.2.2 Oncogene enrichment 
Among the 58 genes in the ovarian cancer module, 52 were not members of the OMIM 
seed set and 13 are known oncogenes (a non-redundant set from OMIM and COSMIC, 
excluding the seed genes). The estimated probability for chance occurrence is smaller 
than 0.001, which means none of the 1000 random modules has higher concentration of 
oncogenes than the ovarian cancer module. The relatively high, but none the less 
significant, p-values reflected the correlation structure of the FLN. Of the (52 – 13 =) 39 
genes that are not firmly established as oncogenes, we estimate that (39×13/52 =) 10 
which have not been previously identified with ovarian cancer, will be drivers. Among the 
oncogene candidates in the module, BRAF and PIK3CA are reported as rare but 
important mutations in the previous study carried out by the TCGA network [50]. 
PIK3CA, PIK3R1, EGFR and ERBB2 are implicated as oncogenes in ovarian cancer 
[112].  
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Table 3-4. Seeds set of ovarian cancer 
Gene symbol Entrez  
Gene ID 
Aberration References 
CTNNB1 1499 Somatic mutation (ser37-to-
cys missense) 
Sagae et al. (1999), 
Wright et al. (1999),  
ERBB2 2064 somatic 2570A-G transition in the 
ERBB2 gene that caused an asn857-
to-ser (N857S) substitution 
Cancer Genome Project 
and Collaborative Group 
(2004)  
AKT1 207 Somatic mutation (glu17-to-lys) Carpten et al. (2007) 
PIK3CA 5290 Somatic mutation (his1047-to-arg, 
gln546-to-lys and glu545-to-lys) 
Campbell et al. (2004) 
RRAS2 22800 Somatic mutation (leu72-to-gln) Chan et al. (1994) 
CDH1 999 Somatic mutation (ser838-to-gly) 
Somatic loss of heterozygosity 
Risinger et al. (1994) 
 
 
Figure 3-4. Ovarian cancer module. Boxes are known oncogenes from OMIM and COSMIC. 
The red nodes are seeds; the blue nodes are genes with high mutation frequencies in the TCGA 
ovarian cancer population; the green nodes are rest of genes in the ovarian cancer module. 
Edges between genes are from the functional linkage network, which represents the functional 
relations between genes, and the thickness of the edge reflects the strength of functional relation 
between two genes.  
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A separate analysis performed by Gabriela Alexis (unpublished data) indicates that 5 of 
the remaining 39 have a significantly high non-silent mutation or amplification/deletion 
rate across all samples in the TCGA (FDR < 0.05). Our results and those obtained by 
analyzing TCGA are independent, and therefore mutually confirmatory. 
3.3.2.3 KEGG pathways that intersect the module 
For the remaining 34 genes, there is no supporting evidence for a causal role in initiation 
or progression of cancer, although 19 are in one or another of the 9 cancer related 
pathways described in the previous section. Not surprisingly, the nine cancer-related 
KEGG pathways are enriched in ovarian cancer module genes (Table S4 Appendix G) 
with FDRs ranging from 0.0004 (apoptosis pathway) to 10-23 (ErbB signaling pathway). 
As suggested in a number of reports, ErbB (EGFR), ERBB2 (HER2) and several 
members of EGFR family are overexpressed or altered in many cancers, including 
ovarian cancer [113]. Our result also suggests that members of the ErbB signaling 
pathway and the EGFR family are tightly connected to other oncogenes in the ovarian 
cancer module and may play critical roles in the development of ovarian cancer. 
3.3.2.4 Comparison with other methods 
We used the same seed set as the input for NetBox. The resulting module includes 97 
genes, 92 of which were not members of the seed set. 28 of them (30.7%) were known 
oncogenes as indicated by OMIM or COSMIC, whereas the ovarian cancer module 
identified by our method has 13 oncogenes (25%). At a rank cutoff of 52 (the size of our 
ovarian cancer module), DFLN had greater specificity than the other two methods (Table 
3-5). 
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We used DAVID to find pathways that are enriched in candidate ovarian cancer drivers 
identified by NetBox. Eight of the nine cancer-related pathways predicted by FLNP were 
also predicted by NetBox (FDR < 0.05). The exception is the Progesterone-mediated 
oocyte pathway. 
Nine genes were found by all three methods, including six oncogenes – EGFR, ESR1, 
PIK3R1, RAF1, LCK and SRC. Among them only PIK3R1 is a well established driver. 
There is independent evidence supporting the candidacy of the other eight genes. 
GSK3B is involved in the Wnt and EGFR signaling pathways, cell migration, hyper-
methylation of CpG island, ER overload response, negative regulation of apoptosis and 
negative regulation of MAPK activity, which is central to cellular transformation. ERBB3 
over expression in a significant proportion of ovarian cancers is correlated with 
proliferation, differentiation and poor prognosis [114–116]. PTK2 (also known as FAK) is 
a focal adhesion kinase and is involved in early step of cell growth. The activation of 
PTK2 is prevalent in ovarian cancers and is related to cell growth, migration, and 
progression [117, 118]. Halder et al. showed that a PTK2 (FAK) inhibitor can suppress 
ovarian cancer growth in vitro and in vivo [119]. 
Table 3-5. Number of oncogenes, ovarian cancer associated genes and genes with high 
alteration rate in TCGA ovarian cancer samples identified by FLNP (A), NetBox (B) and 
DFLN (C). 
 FLNP (A) NetBox (B) DFLN (C) (A,B) (A,C) (A,B,C) 
Module size 
(excluding seeds) 52 91 52 14 17 9 
Known oncogenes 13 (25%) 28 (30.7%) 30 (57.7%) 8 9 6 
GAD 1 (1.9%) 6 (6.6%) 8 (15.4%) 1 1 1 
TCGA 9 (17.3%) 14 (15.4%) 14 (26.9%) 2 5 2 
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Figure 3-4 and table 3-6 show that genes with high mutation rate in the TCGA ovarian 
cancer cohort (blue nodes) have strong connections with seed genes (red nodes) and 
other oncogenes (boxes). The result shows that the ErbB signaling pathway is critical in 
the ovarian cancer module. Several studies have reported that the ErbB signaling 
pathway is critical in development of many cancer types, including ovarian cancer [120–
122]. We found a number of genes that have not been connected to ovarian cancer by 
large scale studies, but for which there is strong evidence implicating them in ovarian 
cancer. For example, the tumor suppressor gene IGF1R has been suggested as a 
potential therapeutic target for ovarian cancer by several studies [123–125]. The protein 
tyrosine kinase PTK6, which functions as an intracellular transducer in epithelial tissues, 
is another candidate driver for ovarian cancer. Ludyga et al. proved that PTK6 directly 
interacts with ERBB2 and knockdown of PTK6 will decrease activation of ERBB2 in 
breast cancer cell lines [126]. It is reasonable to presume that PTK6 may have similar 
interaction with ERBB2 in ovarian cancer. Irie et al. further showed that PTK6 can form a 
complex with IGF1R and modulate anchorage-independent survival of breast cancer and 
ovarian cancer [127]. Our result indicates that PTK6 is tightly connected to AKT1, which 
is a driver of ovarian cancer. Thus, we speculate that PTK6 contributes to the 
development of ovarian cancer via interacting with AKT1, IGF1R and/or ERBB2. 
Considering both breast cancer and ovarian cancer, the FLNP algorithm and Netbox 
showed comparable performance. In addition, although they predicted a common core 
set of candidates, many of the candidates they predict are complementary. It would 
therefore appear that there is some gain in using both methods. 
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Table 3-6. Ovarian cancer module genes with high mutation rate or amplification/deletion 
in TCGA ovarian cancer population. 
Gene Function Abnormal type in TCGA 
ovarian cancer population 
FDR Comments 
PTK6 Protein 
kinase 
Amplification 0.000195  
CDK5 
 Amplification 0.000152  
WNK1 Protein 
kinase 
Amplification 1.25E-06  
IGF1R Tumor 
suppressor 
Amplification 3.26E-06 Potential 
therapeutic target 
[123–125] 
AKT1* Oncogene Amplification 0.042123 Carpten et al. 
(2007) [128] 
WDR51A 
 Deletion 0.001159  
RAF1 Tumor 
suppressor 
Deletion 0.000802  
ABL1 Tumor 
suppressor 
Deletion 5.70E-10 Le et al. (2011)[129] 
CDH1* Tumor 
suppressor 
Deletion 0.000304 Risinger et al. 
(1994) [130] 
PIK3R1 
 Deletion 1.55E-66 Bast et al. (2009) 
[112] 
TCF7L2 Protein 
kinase 
Deletion 1.14E-05  
*Seed genes 
 
3.5 Conclusions  
We provide a quantitative formulation of the idea that oncogenes clustered on an 
evidence weighted functional linkage network are embedded in a field of genes and 
pathways that are likely to be associated with cancer cell physiology. More specifically 
we present a method for determining the boundary of the field, thereby obtaining a 
module that is functionally rich in drivers, and enabling the identification of new 
oncogene candidates. We estimate that 20 of the 42 and 10 of the 39 module genes that 
have not been previously identified with breast and ovarian cancer respectively, will be 
drivers. The results also reveal the detailed interrelations within and among the three 
tiered information hierarchy of genes, networks and modules underlying these two forms 
of cancer.  
61 
 
Chapter 4. Expansion of KEGG pathways 
4.1 Introduction 
Pathways describe the interactions between a group of genes, enzymes and/or 
molecules that carry out a particular cellular task, i.e. apoptosis, fructose metabolism or 
focal adhesion, or contribute to a specific disease phenotype. Pathways are routinely 
used in so-called gene set analysis to detect which pathways are perturbed in a disease 
[23, 24, 131, 132]. Many pathways are manually curated, which allows for highly 
confident and clearly annotated functions of pathways and components in each pathway 
[29, 32, 33, 133]. Because of this, however, these pathway annotations are limited to 
both incomplete current biological knowledge and the requirement of substantial 
manpower. Due to this, manually curated pathways are usually small and the coverage 
is low. Figure 4-1 shows that most current manually curated human pathways can only 
cover up to around 7,000 genes, which is about one-third of the human genome, and the 
average size of pathways are from 7 to 81. 
Another issue plaguing manually curated functional pathways is the lack of standard 
criteria when collecting and translating the data from literature. Therefore, the same 
pathway may have different elements in different databases. For example, the well-
known citric acid (TCA) cycle has 31 genes in KEGG and 19 genes in Reactome, yet 
has only 8 genes in BioCarta. Seven of these genes are treated as members of TCA 
cycle in all three databases but many more genes are assigned to it by only one or two 
databases. 
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Figure 4-1 Statistics of current manually curated human pathway databases. 
The advent of high-throughput experiments enables the measurement of a great number 
of physical interactions and functional associations between proteins, genes, and small 
molecules. Many computational approaches have been developed to identify functional 
modules or disease modules from interaction maps such as protein-protein interaction 
(PPI) networks, gene regulation networks, or functional linkage networks (FLNs) [49, 86, 
87, 134–138]. A number of studies demonstrated that network-based approaches can 
successfully detect genes known to be associated to a disease or participate in a given 
cellular function as well as suggest novel candidate genes for the same [5, 75, 77]. The 
module detection algorithms can be classified into two major categories: divisive 
methods and agglomerative methods. Divisive methods try to partition graphs into 
regions of differing connectivity and optimize the modularity, while agglomerative 
methods try to grow modules from densely interconnected regions. Most of divisive 
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methods need to define a modularity function and try to find a best partition that can 
optimize the modularity, which is the fraction of edges found to be within modules minus 
the expected fraction if edges are randomly placed [139, 140]. A good network partition 
must comprise many within-module edges and as few as possible between-module 
edges.  
However, divisive methods have several drawbacks. Frist, divisive methods usually 
perform a greedy optimization and require complete knowledge of the entire network. If a 
network is huge, divisive method could be very time consuming. Second, divisive 
methods aim to achieve global optimization and attempt to assign all nodes in a network 
into some cluster. This could result in many false positives if we do not have 
comprehensive knowledge of the entire network. Third, it only considers network 
topology and most of divisive methods cannot deal with weighted networks. Also, 
divisive method partitions a network into several subnetworks, so it cannot allow 
overlapped modules. Biological modules are usually highly overlapped, which means a 
gene or protein may participate in several similar or different functions (modules). 
Therefore, those methods may not be suitable for detecting functional modules. To 
address this issue a number of agglomerative algorithms have been proposed to detect 
overlapped modules on a biological network, e.g. MCODE, HUNTER, SPICi and 
ClusterOne [141–146]. Unlike divisive methods, agglomerative methods aim to find local 
dense regions on a network. These methods predicted a number of functional modules; 
however, due to the limitation of current knowledge, it is difficult to annotate the resulting 
functional modules and therefore constrains their applications.  
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In contrast to most of the previous studies that aimed at searching for all possible 
topological modules or functional modules on a network, we focus on suggesting new 
members for existing pathways. In this study we propose a context-based locally optimal 
algorithm that starts from a small set of pathway genes as seeds and followed by 
searching for functionally related genes on the functional linkage network. We use the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database as an example 
and select genes from KEGG pathway database release 64.0 as seeds. We 
demonstrated that our algorithm can successfully identify genes participating in a 
particular pathway with evidence from KEGG pathway database release 68.0 and other 
pathway databases, as well as corresponding Gene Ontology (GO) annotations. 
4.2 Materials and Methods 
4.2.1 KEGG pathway database 
KEGG pathway database is one of the most popular pathway annotation databases. 
KEGG updates its database about five times every year. In its Release 64.0 on October 
1, 2012, KEGG has 206 human pathways and 4,794 genes, where in the Release 68.00 
published one year later (October 1, 2013), there are 276 human pathways in the KEGG 
pathway database covering 6,715 genes. In order to better evaluate the performance of 
our algorithm, we expand pathways in KEGG Release 64.00 and compare our results 
with the latest Release 68.00 as well as other pathway databases (HumanCyc, NCI 
pathway database, BioCarta, Reactome and Pathway Commons) and GO. 
4.2.2 Functional Linkage Network 
Module identification methods have been applied on different types of networks, e.g. PPI 
networks, co-expression networks, gene regulatory network, and FLNs [49, 86, 87, 134–
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138]. The FLN integrates a variety of genomic data and represents the functional 
connections between genes (nodes) by evidence weighted links [79, 147]. In the FLN we 
used in this study, the link weights were established by integrating 16 genomic features 
using a Naïve Bayesian classifier [147]. Previous studies have shown that such 
integrated FLNs can provide more reliable information than a single source network 
[148, 149]. Notably, the sources used to construct the FLN did include any of the 
pathway databases used in this study. Furthermore, the FLN used in this study was 
constructed in 2009, which means the information used to improve KEGG Release 
64.00 to Release 68.00 is not included in the FLN. 
4.2.3 Implementation of algorithm 
4.2.3.1 Expansion of pathway modules 
In this study we modified the module identification algorithm, FLNP, which we described 
in Chapter 3. In short, for a module }{kM = , consisting of k genes, the set of 
neighboring exterior genes )(kNG , we define a modularity score, Sd  as 
∑∑ ∈∈−∈∈=
ji
ji
ji
ji NjMiqMjMipSd
,
,
,
,
]][[1]][[
2
1
ωω  
where ω  is the weighted adjacency matrix, p  is total number of edges within the 
module M , and q  is the total number of edges between module M  and the 
neighborhood community )(kNG . The element ji ,ω in the weighted adjacency matrix  
represents the weight of the edge between genes i  and j .  
ω
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We expect the modularity scoring function we defined should fit to well-defined functional 
modules, such as pathways. Therefore we calculated the modularity score of 245 KEGG 
pathways and found that 242 of 245 (98.8%) KEGG pathways have a modularity score 
greater than 0, with an average Sd  of 1.27 (Figure 4-2). 
 
Figure 4-2 Distribution of modularity score Sd  of 245 KEGG pathways, retrieved April 
2013. 
  
FLNP starts by selecting a small number of connected seed genes on the FLN without 
applying any cutoff on edge weight and recruits genes for maximizing the target function 
Sd  , subject to the constraint that it must be greater than θ . θ  is the threshold for 
defining a module, where we set θ  as 0.1 for getting better specificity. Our previous 
work has shown that with a given context, e.g. oncogenes for a particular cancer types, 
FLNP can successfully identify group of genes that are enriched in that context (Details 
are described in Chapter 3). In this study, our goal is to expand an existing KEGG 
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pathway, therefore we choose a small number of connected genes from a particular 
KEGG pathway as seeds and use FLNP to identify candidate genes for additional 
pathway membership.  
The sensitivity and specificity of the identified modules are correlated to the context of 
input seeds, which is again correlated to the number of input seeds. The larger number 
of input seeds will result in a stronger context. We used the KEGG cell cycle pathway as 
an example to demonstrate the effect of the input seeds context on the resulting module. 
First, we divided the cell cycle pathway into two parts, a training set that contained 89 
genes and a test set that contained 30 genes. To evaluate the effect of the number of 
seeds, we applied our algorithm on the training set with different number of seeds (seed 
number = 1, 2, 3 … 89) 100 times each, and then calculated the average sensitivity and 
specificity for each seed set. Figure 4-3 shows the relationship between the number of 
seeds and the specificity and sensitivity of the identified modules. As the number of 
seeds is reduced, there is a corresponding increase in sensitivity but a decrease in 
specificity. To obtain a balance between sensitivity and specificity, we take into account 
the pathway size when selecting the seeds and use a weighted factor λ  to adjust the 
number of seeds of pathways with different size.  






= λ
p
p
N
SN   
, where pSN  is the number of seeds for the pathway P  and pN  is the size of the 
pathway P . λ  is a weighted factor and varied with pN , where 
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 λ  = 4 ×  
We iteratively choose pSN  genes from a pathway P  as seeds and attempt to detect a 
candidate module for 500 times.   
 
Figure 4-3 Sensitivity and specificity with different context of seed genes. We used the 
KEGG cell cycle pathway as an example to demonstrate the effect of input seeds context on the 
resulting module. The specificity increases with the seed size while the sensitivity behaves in the 
opposite way. 
 
4.2.3.2 Merge pathway modules 
Each of the 500 modules we obtained by applying our algorithm contains genes that are 
associated to part of the target pathway. Here we use a majority rule to merge the 
modules. More specifically, we count the number of times a gene has been elected by 
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our algorithm as a candidate for a particular pathway. Genes that are selected by our 
algorithm more than n times will be included in the final module.   
 
Figure 4-4 Overview of the algorithm. 
 
Defining the threshold n is an important task. Here we use k-fold cross validation to 
determine the best threshold n. For a particular pathway, we partition the pathway into k 
equal size subgroups. Of the k subgroups, a single subgroup is retained as validation 
data and the remaining k-1 subgroups are used as training data. The number of 
subgroups is set to five for pathways with size smaller than 100 and set to ten for 
pathways with size larger than 100. We selected the threshold n at the point of inflection, 
which is widely used for determining the number of clusters  [150]. The median n of all 
cross-validation results is then used. Figure 4-4 illustrates the steps of our algorithm.  
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4.3 Results and discussions 
4.3.1 Comparison with other methods 
We applied our algorithm on 105 KEGG pathways in KEGG release 64.00 excluding (a) 
disease pathway because they are not functional modules and (b) pathway with genes 
fewer than 20 because those pathways cannot provide enough context for expansion. 
Our algorithm is able to expand 100 KEGG pathways and the expanded pathway size is 
from 32 to 826. 48 of 100 expanded KEGG pathways contain genes that are added into 
the same pathway in KEGG release 68.00. In total, 6,272 genes were covered in our 
results.  
We performed a density-based network clustering (k-means) on the FLN and found 33 
clusters on the FLN. We used a hypergeometric test to find the best matching KEGG 
pathway for each cluster. The sizes of the identified clusters were from 3 to 320 and the 
average size was 51. On average, 64% of the cluster genes overlapped with the 
matched KEGG pathway. This high overlap rate implies that modular structures in the 
FLN we used indeed represent certain biological function. Although the simple density-
based method can identify functional clusters that are highly overlapping with KEGG 
pathways, it can only match to 26 KEGG pathways and expand 23 KEGG pathways. 
We also compared our results with a comparative method, PathExpand, which extends 
pathways by including densely interconnected interaction partners on a PPI network 
[151]. PathExpand is able to expand 159 BioCarta pathways, 90 KEGG pathways and 
52 Reactome pathways. In the following example, we demonstrated the results of our 
algorithm on a KEGG metabolic pathway, glycolysis, and a KEGG signaling pathway, 
apoptosis, and compared our predictions with PathExpand. 
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4.3.2 Expansion of KEGG glycolysis pathway 
Glycolysis is a metabolic pathway that describes the process of converting glucose into 
pyruvate. In each of 500 iterations, we randomly selected 16 seed genes from the 64 
genes of the glycolysis pathway in the KEGG pathway database release 64.0. Then, we 
partitioned the glycolysis pathway into five equal size subgroups and performed the 
cross-validation procedure. Figure 4.5 shows the receiver operating characteristic (ROC) 
curves of the cross-validation experiments and indicates that our algorithm can 
successfully recover genes in the test data with high sensitivity and specificity.  
 
Figure 4-5 ROC curves of cross-validation of glycolysis pathway. AUC is the area under 
curve. 
 
From cross-validation we estimate that the best threshold n for the glycolysis pathway is 
30. In total, our algorithm reported 20 genes as candidate members for inclusion in the 
glycolysis pathway. Among these 20 genes, PDHX and GAPDHS are included in the six 
new genes for the glycolysis pathway in the latest KEGG pathway database release 68.0. 
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Five genes, EDARADD, OGDH, MDH2, MDH1 and OGDHL, are not yet included in any 
pathway database but are members of the gene ontology (GO) term “glycolysis” 
(GO:0006096). The expanded KEGG pathway is shown in Figure 4.6. 
Our algorithm not only included genes that have strong evidence from other manually 
curated databases supporting their role in glycolysis but also suggested novel genes and 
possible interactions. For example, transketolase (TKT)  is an enzyme that connects the 
pentose phosphate pathway to glycolysis [152]. Our results suggested that TKT may 
contribute to glycolysis via the interactions with TPI1, PDHX, OGDH and FBP1. In a very 
recent study, Bogorad et al. constructed a non-oxidative glycolysis (NOG) pathway both 
in vitro and in vivo in Escherichia Coli  [153]. The NOG pathway provides a more 
efficient way for carbon conservation in sugar metabolism and is important for carbon 
management. NOG consists of eight core enzymes including F/Xpk, Tkt, Tal, Rpi, Tpi, 
Fba, Fbp and Rpe, which matches to our hypothesis of the role of TKT in glycolysis.   
PathExpand suggested only two new genes, PDK3 and PDK4, to the KEGG glycolysis 
pathway with default settings. However, these two genes were not found in our results, 
nor were they found in any glycolysis related pathways in other pathway databases, e.g. 
HumanCyc, NCI pathway interaction database, BioCarta, Reactome, or the “glycolysis” 
GO term. 
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Figure 4-6 Expanded KEGG glycolysis pathway. Green nodes are KEGG glycolysis pathway 
genes. Blue nodes are candidate glycolysis genes identified by our algorithm. Orange nodes are 
glycolysis genes identified by our algorithm which were added into the glycolysis pathway in 
KEGG release 68.0. Red nodes with bold text are GO glycolysis genes identified by our algorithm. 
Pink links are interactions in the KEGG glycolysis pathway and gray links are interactions 
retrieved from the FLN. In order to clearly show the interactions between genes, we remove weak 
links on the FLN (normalized linkage weight < 0.01). 
 
4.3.3 Expansion of KEGG apoptosis pathway 
Apoptosis is the process of cell death that occurs naturally in living cells. The 
malfunction of apoptosis may cause atrophy or uncontrolled cell proliferation, which is 
very common in cancer development. We randomly selected 22 seed genes from the 89 
genes present in the apoptosis pathway in the release 64.0 of KEGG. Again, the 
apoptosis pathway was partitioned into five equal size subgroups and performed the 
cross-validation experiments. Figure 4-7 shows the ROC curves of the cross-validation 
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experiments and indicates that our algorithm can successfully recover genes in the test 
data with very high specificity and decent sensitivity.   
 
Figure 4-7 ROC curves of cross-validation of apoptosis pathway. AUC is the area under 
curve. 
 
Our cross-validation experiments estimated that the best threshold n for the apoptosis 
pathway is 3. Our algorithm reported 13 new genes as candidate members for the 
apoptosis pathway. Although we did not identify the three new members of the apoptosis 
pathway of KEGG release 68.0, other pathway databases provide evidence to support 
our findings. We collected pathways from several widely used manually curated 
databases, including HumanCyc [154], NCI pathway interaction database [155], 
BioCarta [156], Pathway commons [157], and Reactome [158]. We found that six of the 
13 genes we identified were suggested to participate in apoptosis by at least one of 
those pathway databases (Table 4-1). One of the remaining seven genes is involved in 
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the “apoptotic process” GO term (GO:0006915). The expanded KEGG pathway is shown 
in Figure 4-8. 
Table 4-1 Predicted genes for the KEGG apoptosis pathway with external evidence. 
Gene symbol Entrez Gene ID References 
TRAF6 7189 BioCarta, NCI  
RAF1 5894 BioCarta 
BAK1 578 Reactome, BioCarta 
PARP1 142 BioCarta, NCI 
NGFR 4804 NCI 
PDPK1 5170 BioCarta, NCI 
MCL1 4170 Apoptotic process (GO:0006915) 
 
We found a number of genes that had not yet been assigned to the apoptosis pathway 
by any of the manually curated pathways or GO, but for which there is strong evidence 
implicating them in the apoptosis pathway. PI3K/AKT/mTOR pathway is an important 
signaling pathway in cancer, which is activated by insulin signaling pathway and 
contributes to cell proliferation, regulation of protein synthesis and apoptosis [159, 160]. 
Previous studies suggested that PI3K activates AKT, then AKT regulates apoptosis by 
phosphorylating BAD, FKHR, and NF-кB, or effects a growth transition by 
phosphorylating mTOR [159]. Our result suggested that the mammalian target of 
rapamycin (mTOR) may regulate apoptosis as well. In some cancers, like myeloma, 
rapamycin can induce apoptosis in cancer cells by activating apoptosis [161, 162]. The 
mechanisms leading to cancer cell death in response to rapamycin treatment, however, 
are not yet clear. Nevertheless, it is known that rapamycin can inhibit mTOR and induce 
apoptosis [163], implying that mTOR may be an apoptosis inhibitor. Some studies have 
proposed that mTOR inhibits apoptosis via its downstream target S6K, which then 
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phosphorylates and inactivates the pro-apoptotic molecule BAD [162, 164, 165]. Figure 
4-8 shows that mTOR interacts with PDPK1 and AKT3, which in turn influence BAD, 
which agrees with the above assumption. 
 
Figure 4-8 Expanded KEGG apoptosis pathway. Green nodes are the KEGG apoptosis 
pathway genes. Blue nodes are candidate apoptosis genes identified by our algorithm. Red 
nodes with bold text are apoptosis genes that identified by our algorithm with evidence from other 
pathway databases. Pink links are interactions in KEGG apoptosis pathway and Grey links are 
interactions retrieved from the FLN. In order to clearly show the interactions between genes, we 
remove weak links on the FLN (normalized linkage weight < 0.2). 
 
PathExpand predicts 39 new genes to add to the KEGG apoptosis pathway. Only one 
gene, NFKB2, was found by both PathExpand and our method. Among the 39 genes 
predicted by PathExpand, only three genes have evidence from other pathway 
databases which supports their roles in apoptosis. The results show that applying a 
module based algorithm on a functional linkage network can strongly improve both 
sensitivity and specificity.  
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4.4 Conclusions 
We adapted a module identification algorithm to the problem of expanding manually 
curated pathways. By starting from a small seed set of a particular pathway, our 
algorithm searched on the FLN and recruited genes that may contribute to that pathway. 
The cross-validation experiments show that our method can recover genes in the test 
data with high specificity and good sensitivity.  
The results of the expansion of three KEGG pathways further show that our method can 
successfully recover genes with strong evidence supporting their roles in a particular 
pathway as well as provide novel additional candidates for that pathway. In summary, 
we demonstrate that (a) genes in the same pathway tend to be clustered on the FLN, 
and (b) our functional weighting based algorithm can detect those clusters on the FLN 
and has a better performance than the density based method. Our results can be used 
as an alternative option for gene set enrichment analysis, and it can help to improve the 
coverage of manually curated pathways. 
We have shown that applying our module identification method in the FLN can 
successfully identify driver modules in cancer (Chapter 3) as well as functional modules 
(e.g. pathways or other ontologies). Because our module identification method is 
context-based, the context of the input seed set is strongly correlated to the outcome. 
Therefore, one can use the algorithm to identify functional modules in any genomic area 
by selecting seeds with related context.   
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Appendices 
APPENDIX A 
Regulator FDR p-value 
ave. corr. 
(regulatees) fraction 
ave. corr. 
(regulator-
regulatees) 
# of 
coherent 
regulatees 
MYC 0.0058 0.0004 0.166 0.0578 0.1161 375 
NFE2L2 0.0032 0.0002 0.159 0.0614 0.2215 277 
PPARG 0.0018 0.0001 0.167 0.0667 0.2582 254 
IL13 0.0032 0.0002 0.1662 0.0636 0.0733 252 
MYCN 0.0018 0.0001 0.175 0.0721 0.1339 239 
IL10 0.0045 0.0003 0.1628 0.0643 0.2825 213 
CDKN1A 0.0018 0.0001 0.1668 0.0695 0.1755 208 
PPARA 0.0119 0.001 0.1514 0.0602 0.2197 206 
CSF2 0.0018 0.0001 0.1783 0.0829 0.1437 194 
IL5 0.0018 0.0001 0.172 0.0757 0.0615 190 
IL2 0.0045 0.0003 0.1692 0.0678 0.0636 190 
ETS1 0.0378 0.0045 0.163 0.0593 0.1618 175 
CLOCK 0.0018 0.0001 0.1786 0.0777 0.102 164 
VEGFA 0.0252 0.0027 0.1699 0.0627 0 164 
NRIP1 0.0018 0.0001 0.2416 0.1812 0.2552 149 
BRCA1 0.0359 0.0042 0.168 0.0626 0.1602 143 
TNFSF11 0.0018 0.0001 0.1753 0.0853 0.0963 139 
CXCL12 0.0421 0.0055 0.1639 0.0621 0.1294 139 
LGALS3 0.0415 0.0053 0.1647 0.0616 0.1098 137 
CDKN2A 0.0374 0.0044 0.1728 0.0649 0.139 131 
DMD 0.0018 0.0001 0.1843 0.0853 0.1827 128 
IRF7 0.0032 0.0002 0.1786 0.0729 0.2607 119 
INS 0.0101 0.0008 0.1712 0.0691 0.1381 118 
CSF1 0.0018 0.0001 0.1822 0.0892 0.2073 115 
XBP1 0.0018 0.0001 0.2056 0.1134 0.2462 112 
GK 0.0032 0.0002 0.1748 0.0802 0.1459 110 
KLF1 0.0489 0.0068 0.1595 0.0652 0.2596 105 
HHEX 0.0288 0.0032 0.1685 0.0672 0.193 104 
PPARGC1A 0.0018 0.0001 0.2055 0.1348 0.1537 102 
PDX1 0.0018 0.0001 0.1853 0.0977 0 98 
NEUROD6 0.0415 0.0053 0.1668 0.0669 0.1756 92 
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SREBF1 0.0018 0.0001 0.1881 0.1059 0.2032 86 
ESRRA 0.0018 0.0001 0.1855 0.1109 0.1303 77 
IL3 0.0252 0.0027 0.1667 0.0729 0.0486 77 
CSF3 0.0112 0.0009 0.1715 0.0769 0.1805 76 
ACVR2A 0.0333 0.0038 0.1798 0.0724 0.122 75 
IRF5 0.0045 0.0003 0.1805 0.0837 0.1079 74 
KITLG 0.0402 0.005 0.1683 0.0705 0.1059 74 
INSR 0.0018 0.0001 0.2271 0.151 0.0902 73 
CCL3L3 0.0378 0.0045 0.1789 0.0724 0 73 
CD40LG 0.0018 0.0001 0.2082 0.1311 0.2672 70 
KDM5B 0.0252 0.0027 0.1767 0.0734 0 69 
MEIS1 0.0479 0.0066 0.1532 0.0687 0.1427 68 
STAT6 0.0395 0.0048 0.1675 0.0725 0.0899 67 
IFNA1 0.0101 0.0008 0.1812 0.0843 0.0368 63 
SPI1 0.0018 0.0001 0.2084 0.138 0.1183 61 
THAP1 0.0018 0.0001 0.223 0.1629 0.2036 59 
SREBF2 0.0032 0.0002 0.1895 0.1066 0.1921 54 
IL15 0.0101 0.0008 0.1795 0.0881 0.2449 53 
FGFR3 0.0499 0.007 0.1732 0.0746 0.0882 53 
FAS 0.0018 0.0001 0.226 0.1645 0.1692 50 
NRF1 0.0018 0.0001 0.2611 0.2256 0.2691 49 
IL29 0.0018 0.0001 0.2341 0.1576 0.0663 44 
IL18 0.0136 0.0012 0.179 0.0876 0.2699 43 
IGF1R 0.0018 0.0001 0.2291 0.1655 0.2818 42 
IL27 0.0018 0.0001 0.2077 0.1398 0.0808 41 
ITGB6 0.0018 0.0001 0.1988 0.1219 0.0691 40 
SCAP 0.0018 0.0001 0.212 0.1443 0 40 
CCNT1 0.007 0.0005 0.1943 0.1122 0.226 40 
CD34 0.0499 0.007 0.1692 0.083 0.1198 40 
CD99 0.007 0.0005 0.1899 0.1027 0.1261 38 
PLIN1 0.0018 0.0001 0.2611 0.203 0 37 
C5 0.0112 0.0009 0.1786 0.0965 0.17 37 
TNFSF10 0.0328 0.0037 0.1851 0.0928 0.1442 37 
CCL5 0.0018 0.0001 0.2286 0.1531 0.2137 36 
TNFSF12 0.0045 0.0003 0.1907 0.111 0.1305 36 
FADD 0.0152 0.0014 0.1842 0.0929 0.1488 34 
APOE 0.0018 0.0001 0.2096 0.1438 0.1055 33 
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RBL2 0.0333 0.0038 0.1844 0.0951 0.2399 33 
VIP 0.0112 0.0009 0.167 0.098 0.1321 31 
MAPK9 0.0304 0.0034 0.1746 0.0922 0.2084 31 
CD5 0.0119 0.001 0.1989 0.1081 0.219 30 
SERPINA1 0.0018 0.0001 0.2227 0.1477 0.2226 29 
THRB 0.0119 0.001 0.1814 0.1126 0.089 29 
MLX 0.0081 0.0006 0.1861 0.1181 0.232 27 
MIF 0.0288 0.0032 0.1834 0.1026 0.1218 27 
NPSR1 0.0032 0.0002 0.1789 0.1229 0 26 
MAP3K7 0.007 0.0005 0.1938 0.1277 0.1361 26 
FOXL2 0.018 0.0018 0.1573 0.0933 0.0801 26 
ANGPTL4 0.0421 0.0055 0.2045 0.1032 0.1661 24 
TLR2 0.0018 0.0001 0.2566 0.2036 0.3803 23 
GNA12 0.0382 0.0046 0.1874 0.0949 0.128 22 
ATM 0.0453 0.0061 0.1687 0.0989 0.1245 22 
CCR3 0.0018 0.0001 0.2031 0.1586 0.1079 21 
JAK2 0.0091 0.0007 0.1974 0.1305 0.1692 20 
NRAS 0.0101 0.0008 0.2334 0.14 0.2698 20 
CORT 0.0018 0.0001 0.2557 0.2428 0.0493 19 
TAB1 0.0018 0.0001 0.2197 0.1957 0 19 
CSF2RB 0.0018 0.0001 0.2615 0.2048 0.1597 18 
PPARGC1B 0.0018 0.0001 0.2534 0.2398 0.1444 18 
CYP19A1 0.0032 0.0002 0.2007 0.16 0.1712 18 
ALDH1A2 0.0197 0.002 0.2194 0.1381 0.1368 18 
IRS2 0.0045 0.0003 0.2174 0.183 0.1787 16 
NFKBIA 0.0119 0.001 0.2109 0.1526 0.2231 16 
GNRHR 0.0146 0.0013 0.2182 0.1282 0.0974 16 
CCR5 0.0288 0.0032 0.2014 0.1225 0.3539 16 
ZNF175 0.0018 0.0001 0.3295 0.3099 0.1765 15 
F7 0.0018 0.0001 0.2639 0.249 0.1317 14 
INSIG1 0.0045 0.0003 0.2478 0.2167 0.146 14 
TBK1 0.0136 0.0012 0.2302 0.181 0.1869 14 
SEMA7A 0.0257 0.0028 0.2385 0.1474 0.0939 14 
NFE2 0.0408 0.0051 0.1851 0.1397 0.2695 14 
CD86 0.0018 0.0001 0.3014 0.2762 0.4353 13 
LPIN1 0.0018 0.0001 0.2394 0.2083 0.322 13 
IL17F 0.0018 0.0001 0.3134 0.2667 0.0415 13 
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TFAM 0.0197 0.002 0.2502 0.1544 0.2087 13 
NPPA 0.0128 0.0011 0.2222 0.1618 0.0455 12 
GABPA 0.0152 0.0014 0.2162 0.1691 0.1811 12 
NR2F6 0.0453 0.0061 0.1879 0.1417 0.2273 12 
INSIG2 0.0018 0.0001 0.2677 0.2692 0.0981 11 
PARP9 0.0018 0.0001 0.2946 0.2667 0.4277 11 
CAT 0.0091 0.0007 0.2069 0.1917 0.2225 11 
TRIM28 0.0168 0.0016 0.2528 0.1667 0.1197 11 
XDH 0.0174 0.0017 0.1996 0.1618 0.0886 11 
EHHADH 0.0018 0.0001 0.2864 0.3333 0.4193 10 
GRP 0.0018 0.0001 0.2488 0.2418 0.0462 10 
HSD17B4 0.0018 0.0001 0.2864 0.3333 0.3351 10 
CAMP 0.0152 0.0014 0.2377 0.1667 0.1999 10 
ELANE 0.0354 0.0041 0.197 0.1818 0 10 
PIAS1 0.0018 0.0001 0.2712 0.2727 0.1313 9 
PLAU 0.007 0.0005 0.2336 0.1838 0.1484 9 
FOSL1 0.0128 0.0011 0.267 0.2444 0.1846 9 
DDX58 0.0252 0.0027 0.2191 0.2 0.1541 9 
TBX21 0.034 0.0039 0.171 0.1438 0.2831 9 
CGB5 0.0402 0.0049 0.2074 0.15 0.2411 9 
PF4 0.0018 0.0001 0.3008 0.3333 0.1183 8 
PRKCB 0.0018 0.0001 0.2646 0.2692 0 8 
PRKCZ 0.0018 0.0001 0.28 0.2909 0.0663 8 
AIMP1 0.0018 0.0001 0.3571 0.3778 0 8 
IGF2BP1 0.0018 0.0001 0.3533 0.3273 0.1303 8 
CXCL2 0.0058 0.0004 0.3299 0.3111 0.512 8 
GCK 0.0081 0.0006 0.2817 0.2778 0.2934 8 
HRH2 0.0081 0.0006 0.2245 0.2444 0.1321 8 
F10 0.0174 0.0017 0.2221 0.2182 0.1744 8 
G6PD 0.0249 0.0026 0.2704 0.2222 0.1572 8 
EREG 0.0252 0.0027 0.2494 0.25 0.3799 8 
NLRP12 0.0421 0.0055 0.2203 0.1818 0 8 
TPPP2 0.0439 0.0058 0.2459 0.1538 0 8 
EPHB1 0.0018 0.0001 0.3842 0.5278 0.0787 7 
HMGB1 0.0018 0.0001 0.2947 0.303 0.1405 7 
TNNI3 0.0032 0.0002 0.2896 0.3611 0.0315 7 
DSP 0.0119 0.001 0.3648 0.3333 0.1436 7 
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PARP2 0.0128 0.0011 0.3133 0.3333 0.1502 7 
HSF2 0.0152 0.0014 0.2902 0.2182 0.2684 7 
DGAT1 0.0152 0.0014 0.2361 0.2222 0.3676 7 
ELF3 0.0231 0.0024 0.1983 0.1758 0.1483 7 
FOXC2 0.0265 0.0029 0.224 0.2222 0.1311 7 
GFI1 0.0419 0.0054 0.2569 0.2143 0.1242 7 
C3 0.0433 0.0057 0.2363 0.1667 0.1715 7 
AKR1B1 0.0464 0.0063 0.2122 0.1944 0.2298 7 
BACH1 0.0018 0.0001 0.4038 0.5238 0.2259 6 
TNXB 0.0018 0.0001 0.5725 0.7333 0.568 6 
BID 0.0032 0.0002 0.377 0.5238 0.3656 6 
GHRH 0.0032 0.0002 0.3222 0.3929 0.438 6 
PLAT 0.0168 0.0016 0.2629 0.2182 0.1346 6 
MLXIPL 0.0168 0.0016 0.2796 0.3333 0.256 6 
ZFPM2 0.0174 0.0017 0.203 0.197 0.2007 6 
SPIC 0.0231 0.0024 0.2315 0.2222 0.0844 6 
TIMP1 0.0453 0.0061 0.2858 0.2381 0.3974 6 
ACACA 0.0018 0.0001 0.5054 0.6 0.4811 5 
TNFRSF8 0.0018 0.0001 0.7131 1 0.1519 5 
FCER2 0.0032 0.0002 0.4649 0.5333 0.1378 5 
GHR 0.0032 0.0002 0.4344 0.6667 0.1591 5 
DGAT2 0.0045 0.0003 0.3564 0.4667 0.5307 5 
CASP8 0.0058 0.0004 0.342 0.381 0.1787 5 
PCK1 0.0091 0.0007 0.3331 0.3333 0.3374 5 
ABCA1 0.0136 0.0012 0.2524 0.2778 0.0853 5 
FASLG 0.0168 0.0016 0.3134 0.3333 0.1243 5 
DACH1 0.0168 0.0016 0.2285 0.2222 0.0937 5 
CCR1 0.018 0.0018 0.327 0.4 0.45 5 
CFB 0.0257 0.0028 0.2593 0.2857 0.4113 5 
B2M 0.0378 0.0045 0.3088 0.3 0.1353 5 
MBTPS1 0.0382 0.0046 0.2416 0.2143 0.1461 5 
TARP 0.0413 0.0052 0.2341 0.3 0 5 
ABCG1 0.0032 0.0002 0.4312 0.6 0.1138 4 
C5AR1 0.0058 0.0004 0.4764 0.6667 0.5814 4 
EIF2AK2 0.0081 0.0006 0.4058 0.4 0.1109 4 
PON1 0.0168 0.0016 0.3573 0.4 0.0289 4 
MT1F 0.0174 0.0017 0.3188 0.4 0.1936 4 
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NRTN 0.018 0.0018 0.2651 0.4 0.0678 4 
PRKG1 0.0206 0.0021 0.3687 0.4 0.0555 4 
TGFB1I1 0.0402 0.005 0.219 0.2143 0.1398 4 
FLT3LG 0.0415 0.0053 0.2597 0.2381 0.3232 4 
PLG 0.0419 0.0054 0.2079 0.2143 0.0538 4 
PPBP 0.0444 0.0059 0.2464 0.2143 0.1414 4 
EHF 0.0464 0.0063 0.2269 0.2143 0.0438 4 
TIRAP 0.047 0.0064 0.3606 0.2143 0.0696 4 
GCLC 0.0018 0.0001 0.8637 1 0.1916 3 
GCLM 0.0018 0.0001 0.8637 1 0.128 3 
ZBED1 0.0018 0.0001 0.6115 1 0.0354 3 
PNPT1 0.0018 0.0001 0.667 1 0.0515 3 
SLC12A2 0.0081 0.0006 0.4535 0.5 0.1619 3 
SLC4A1 0.0091 0.0007 0.4418 0.5 0.2792 3 
RTKN 0.0119 0.001 0.3728 0.5 0.1417 3 
DRD1 0.0128 0.0011 0.5053 0.5 0.0747 3 
CBFB 0.0146 0.0013 0.4325 0.5 0.1673 3 
UXT 0.0189 0.0019 0.5082 0.6667 0.0433 3 
ZIC1 0.0214 0.0022 0.3747 0.6667 0.0265 3 
MT1E 0.0257 0.0028 0.4084 0.6667 0.152 3 
ARRB2 0.032 0.0036 0.3149 0.3 0.3479 3 
TYMP 0.0354 0.0041 0.1778 0.3 0 3 
SERPIND1 0.0359 0.0042 0.2313 0.3 0.0612 3 
TANK 0.0395 0.0048 0.319 0.3 0.0772 3 
CASP10 0.0402 0.005 0.3267 0.3 0.114 3 
KLF6 0.0402 0.005 0.2461 0.3 0.1744 3 
MDK 0.0413 0.0052 0.2397 0.3 0.0611 3 
ACTC1 0.0018 0.0001 0.8186 1 0 2 
ACTG2 0.0018 0.0001 0.8186 1 0.9093 2 
CKS1B 0.0018 0.0001 0.5419 1 0.0915 2 
CKS2 0.0018 0.0001 0.5419 1 0.4229 2 
CMA1 0.0018 0.0001 0.7911 1 0.2685 2 
COL2A1 0.0018 0.0001 0.7911 1 0.0977 2 
COL4A3 0.0018 0.0001 0.9219 1 0.0664 2 
EMD 0.0018 0.0001 0.4409 1 0.1359 2 
FCGR3A 0.0018 0.0001 0.6979 1 0.2433 2 
G6PC 0.0018 0.0001 0.6594 1 0.3004 2 
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HIST1H1C 0.0018 0.0001 0.6185 1 0.2032 2 
HTR2C 0.0018 0.0001 0.5514 1 0.0286 2 
IK 0.0018 0.0001 0.6056 1 0.0581 2 
IL12RB1 0.0018 0.0001 0.6583 1 0.1491 2 
MB 0.0018 0.0001 0.563 1 0.0208 2 
NMB 0.0018 0.0001 0.8704 1 0.1293 2 
ODC1 0.0018 0.0001 0.5283 1 0.1498 2 
OMG 0.0018 0.0001 0.8007 1 0.055 2 
PLA2G2A 0.0018 0.0001 0.6166 1 0.1777 2 
PLP1 0.0018 0.0001 0.5454 1 0.0966 2 
TRPM2 0.0018 0.0001 0.8177 1 0.0566 2 
TSC1 0.0018 0.0001 0.5283 1 0.1606 2 
TXK 0.0018 0.0001 0.5334 1 0.1316 2 
NPHS2 0.0018 0.0001 0.4347 1 0.0287 2 
CFLAR 0.0018 0.0001 0.5688 1 0.1169 2 
RPS6KA4 0.0018 0.0001 0.8704 1 0.1618 2 
F2RL3 0.0018 0.0001 0.8605 1 0.0776 2 
RPS6KA5 0.0018 0.0001 0.8704 1 0.0441 2 
ZFYVE16 0.0018 0.0001 0.5054 1 0.0801 2 
SH2B2 0.0018 0.0001 0.8007 1 0 2 
CD160 0.0018 0.0001 0.8704 1 0.0258 2 
TPSD1 0.0018 0.0001 0.4796 1 0.0404 2 
TOR2A 0.0018 0.0001 0.8007 1 0.0532 2 
ARID5B 0.0018 0.0001 0.6033 1 0.076 2 
CREB3L1 0.0018 0.0001 0.5488 1 0.2695 2 
VSX2 0.0018 0.0001 0.4514 1 0 2 
KDM1A 0.0433 0.0057 0.2832 0.3333 0 2 
USP11 0.0479 0.0066 0.2602 0.3333 0.3514 2 
FGF18 0.0479 0.0066 0.2315 0.3333 0.0379 2 
MSR1 0.0484 0.0067 0.3703 0.3333 0.591 2 
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APPENDIX B 
Regulator FDR p-value 
ave. corr. 
(regulatee) fraction 
ave. corr. 
(regulator-
regulatee) 
# of 
regulatees 
TNF 0.0011 0.0001 0.1284 0.1206 0.1488 810 
TGFB1 0.0011 0.0001 0.1333 0.129 0.2157 643 
IFNG 0.0011 0.0001 0.1614 0.1927 0.1821 555 
IL1B 0.0011 0.0001 0.1316 0.1279 0.2055 408 
IL6 0.0011 0.0001 0.1422 0.1465 0.1612 325 
IL13 0.0011 0.0001 0.1522 0.1681 0 278 
IL4 0.0011 0.0001 0.1611 0.1918 0 274 
IL1A 0.0011 0.0001 0.1426 0.1574 0.1224 257 
IFNB1 0.0011 0.0001 0.1516 0.1697 0 249 
MYCN 0.0018 0.0002 0.1362 0.1328 0.1015 248 
F2 0.0128 0.002 0.1325 0.1262 0 234 
CDKN1A 0.0011 0.0001 0.1746 0.2228 0.108 233 
IL10 0.0011 0.0001 0.185 0.2508 0.2602 227 
FGF2 0.0033 0.0004 0.1348 0.1329 0.1198 227 
IL5 0.0275 0.0054 0.1334 0.124 0 201 
CSF2 0.0011 0.0001 0.1648 0.2001 0 196 
IL2 0.0011 0.0001 0.1684 0.1998 0 185 
MAPK1 0.0011 0.0001 0.1723 0.215 0.1101 179 
VEGFA 0.0059 0.0008 0.1356 0.1364 0.0877 177 
STAT5A 0.0297 0.0061 0.134 0.1286 0.1326 163 
TNFSF11 0.0011 0.0001 0.1593 0.1986 0.0757 148 
DMD 0.0011 0.0001 0.1543 0.1795 0.0807 146 
E2F1 0.0163 0.0027 0.1394 0.1413 0.2017 136 
E2F4 0.0011 0.0001 0.1685 0.2067 0.08 130 
IRF7 0.0011 0.0001 0.2097 0.2899 0.2619 130 
RELA 0.0011 0.0001 0.1437 0.1589 0.1123 129 
CSF1 0.0011 0.0001 0.1691 0.1871 0.234 120 
IFNA2 0.0011 0.0001 0.2372 0.3505 0 118 
IKBKB 0.0018 0.0002 0.1468 0.1686 0.0786 112 
EP300 0.004 0.0005 0.1446 0.1594 0.0758 106 
AGT 0.0011 0.0001 0.1577 0.1896 0.0816 105 
SOCS3 0.0011 0.0001 0.1527 0.1781 0.1643 103 
EDN1 0.0011 0.0001 0.1674 0.2124 0.1599 102 
CHUK 0.0018 0.0002 0.1513 0.1769 0.072 100 
FGF1 0.0471 0.0118 0.1368 0.1389 0.2085 97 
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SRC 0.0289 0.0058 0.1457 0.1493 0.1043 96 
NCOR1 0.0088 0.0013 0.1492 0.1641 0.116 93 
STAT1 0.0011 0.0001 0.2121 0.3137 0.3147 90 
PTGS2 0.0364 0.0079 0.1356 0.1465 0.1487 83 
CD40LG 0.0011 0.0001 0.2297 0.3547 0 80 
CSF3 0.0018 0.0002 0.1643 0.1975 0 78 
IL3 0.0026 0.0003 0.1514 0.1816 0 78 
IFNA1 0.0011 0.0001 0.2187 0.326 0 76 
STAT6 0.0011 0.0001 0.1781 0.2401 0.088 76 
THAP1 0.0011 0.0001 0.2848 0.4717 0.0959 76 
DYSF 0.0046 0.0006 0.1515 0.1764 0.1377 75 
REL 0.0278 0.0055 0.1442 0.1576 0.1125 74 
TGFB2 0.0033 0.0004 0.1574 0.1826 0.0978 72 
SMAD3 0.0011 0.0001 0.1714 0.2074 0.0896 71 
JUN 0.0011 0.0001 0.1682 0.2083 0.096 68 
IKBKG 0.0053 0.0007 0.1501 0.1834 0.1075 68 
TLR4 0.0011 0.0001 0.2073 0.3009 0.3535 67 
IL1RN 0.0011 0.0001 0.2628 0.3863 0.28 66 
OSM 0.0011 0.0001 0.1654 0.2221 0 65 
PTH 0.0128 0.002 0.1556 0.1766 0 62 
IL15 0.0011 0.0001 0.1864 0.2438 0.282 60 
IL17A 0.0011 0.0001 0.1746 0.2458 0 59 
BRMS1 0.0175 0.0029 0.1598 0.1702 0.0651 59 
ERBB3 0.0011 0.0001 0.1781 0.2212 0.0998 57 
IRF8 0.0011 0.0001 0.1697 0.214 0.3138 54 
FAS 0.0011 0.0001 0.2742 0.4511 0.2914 53 
SPI1 0.0011 0.0001 0.3227 0.4904 0.4947 53 
SMAD7 0.0331 0.007 0.1607 0.1712 0.1411 52 
IL18 0.0011 0.0001 0.2321 0.381 0.2549 50 
TGFB3 0.0011 0.0001 0.2354 0.3491 0.2858 50 
ERBB4 0.0018 0.0002 0.1808 0.2327 0.1124 50 
NRF1 0.0066 0.0009 0.1647 0.2021 0 50 
IL29 0.0011 0.0001 0.5344 0.8831 0 49 
IL7 0.0046 0.0006 0.1776 0.2202 0.2266 49 
IRF1 0.0011 0.0001 0.2634 0.4253 0.4006 48 
FADD 0.0088 0.0013 0.1654 0.1983 0.0749 48 
CD40 0.0128 0.002 0.1571 0.1873 0.1693 48 
TNFRSF1A 0.0026 0.0003 0.1715 0.2264 0.1495 47 
RB1 0.0011 0.0001 0.1808 0.2569 0.1588 46 
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MAP2K1 0.0053 0.0007 0.1712 0.2151 0.0557 46 
IL27 0.0011 0.0001 0.3201 0.5347 0 45 
KLF2 0.0011 0.0001 0.1796 0.2451 0.26 44 
ITGB6 0.0011 0.0001 0.2578 0.4201 0.2582 43 
TNFSF10 0.0011 0.0001 0.2345 0.3788 0.322 43 
C5 0.0011 0.0001 0.184 0.2627 0.0681 42 
BNIP3L 0.0018 0.0002 0.1846 0.2302 0.0797 41 
APOE 0.0011 0.0001 0.2377 0.3426 0.3081 40 
IFNA13 0.0011 0.0001 0.2582 0.4297 0 40 
S100B 0.0341 0.0073 0.1626 0.185 0.1257 40 
CTGF 0.0434 0.01 0.1675 0.1798 0.2495 40 
HTT 0.0011 0.0001 0.1896 0.247 0 39 
IRF3 0.0297 0.0061 0.1725 0.1884 0.0957 39 
TNFSF12 0.0011 0.0001 0.2722 0.4679 0.2291 37 
FOXP3 0.0011 0.0001 0.1903 0.2432 0 37 
CCL5 0.0018 0.0002 0.1833 0.2525 0.2789 37 
TCF3 0.0083 0.0012 0.1823 0.2106 0.0902 37 
VIP 0.0011 0.0001 0.2019 0.2776 0 35 
HOXD3 0.0018 0.0002 0.2067 0.2973 0.1129 35 
MAP3K7 0.0011 0.0001 0.25 0.4082 0.085 33 
SPDEF 0.0011 0.0001 0.2248 0.3131 0 33 
SMAD4 0.0018 0.0002 0.1837 0.2709 0.0793 33 
NFKB1 0.0033 0.0004 0.1941 0.2632 0.2394 33 
RBL2 0.0078 0.0011 0.1746 0.2179 0.1133 33 
LPL 0.0184 0.0031 0.1711 0.2033 0.1149 33 
SATB1 0.0321 0.0067 0.1758 0.1991 0.092 32 
NPSR1 0.0018 0.0002 0.1935 0.2648 0 31 
CD5 0.0118 0.0018 0.1926 0.2302 0.2713 30 
FOXL2 0.015 0.0024 0.1585 0.2176 0.1192 30 
MYD88 0.0011 0.0001 0.2282 0.3747 0.2271 29 
PTK2 0.0159 0.0026 0.1835 0.2298 0.0947 29 
PDGFB 0.0011 0.0001 0.2122 0.3106 0.2156 28 
FOXM1 0.0046 0.0006 0.197 0.2644 0.308 28 
THRA 0.0409 0.0091 0.1439 0.195 0.1148 28 
ATM 0.0011 0.0001 0.2577 0.3419 0.0838 27 
SOCS1 0.0011 0.0001 0.2203 0.2989 0.1808 26 
IL21 0.0011 0.0001 0.2433 0.381 0 26 
LTA 0.0018 0.0002 0.2045 0.3228 0 26 
GPX1 0.0094 0.0014 0.185 0.2506 0.1878 26 
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HSF1 0.0439 0.0102 0.1641 0.2116 0.0887 26 
ADIPOQ 0.0184 0.0031 0.1772 0.228 0.1679 25 
RBL1 0.0011 0.0001 0.2754 0.4954 0.3379 24 
TLR2 0.0011 0.0001 0.3218 0.56 0.4882 24 
CCR2 0.0011 0.0001 0.2698 0.4433 0.3448 24 
LIPG 0.0263 0.0051 0.1729 0.2194 0.1466 24 
CD34 0.0321 0.0067 0.1675 0.2222 0.1642 24 
BCL6 0.0417 0.0094 0.1534 0.2046 0.0877 24 
GAPDH 0.0011 0.0001 0.2597 0.4167 0.0853 23 
TAB1 0.0011 0.0001 0.3017 0.5181 0 23 
CCL13 0.0018 0.0002 0.2367 0.3518 0.1887 22 
CORT 0.0011 0.0001 0.3158 0.5801 0 21 
TLR3 0.0011 0.0001 0.2547 0.4372 0.3063 21 
DKK1 0.0469 0.0117 0.1704 0.2138 0.1019 21 
F7 0.0011 0.0001 0.2337 0.3939 0 20 
ALDH1A2 0.0011 0.0001 0.2857 0.4286 0.1411 20 
CCL11 0.01 0.0015 0.2002 0.2717 0.3139 20 
GNRHR 0.0289 0.0058 0.1815 0.2355 0 20 
CXCL10 0.0392 0.0086 0.1908 0.22 0.3279 20 
CCR5 0.0018 0.0002 0.2285 0.3238 0.3969 19 
BAX 0.0018 0.0002 0.2256 0.3571 0.0947 18 
RORA 0.0206 0.0037 0.171 0.2632 0.1178 18 
IL12A 0.0011 0.0001 0.2283 0.3987 0.1417 17 
IL12B 0.0011 0.0001 0.2494 0.4 0 17 
IL1R1 0.0059 0.0008 0.2152 0.3333 0.0693 16 
CRH 0.0133 0.0021 0.1963 0.2865 0 16 
IHH 0.0255 0.0049 0.1836 0.2745 0 16 
SEMA7A 0.0266 0.0052 0.207 0.2474 0 16 
PRKCD 0.0422 0.0096 0.1637 0.2294 0.1003 16 
NFKBIA 0.0011 0.0001 0.2838 0.5515 0.3262 15 
XDH 0.0011 0.0001 0.297 0.55 0.166 15 
ABCB1 0.0018 0.0002 0.2629 0.3476 0.1998 15 
CSF2RB 0.0046 0.0006 0.2207 0.3095 0 15 
E2F2 0.0066 0.0009 0.2118 0.3268 0.2793 15 
E2F3 0.0066 0.0009 0.209 0.3309 0.1528 15 
BTC 0.0088 0.0013 0.2302 0.3333 0.0817 15 
F2R 0.025 0.0048 0.1942 0.2632 0.2201 15 
THBS1 0.0011 0.0001 0.2645 0.4667 0.3828 14 
C5orf13 0.0011 0.0001 0.3452 0.5333 0.1319 14 
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IL17F 0.0011 0.0001 0.3312 0.5619 0 14 
CEBPE 0.0046 0.0006 0.2137 0.3583 0 14 
RUNX1 0.0187 0.0032 0.2011 0.3083 0.2246 14 
HBP1 0.0431 0.0099 0.1911 0.2667 0.1022 14 
CAMP 0.0011 0.0001 0.3524 0.7051 0 13 
ZNF175 0.0011 0.0001 0.4129 0.5714 0.1094 13 
IL17RA 0.0011 0.0001 0.2942 0.5641 0.2207 13 
TBK1 0.0011 0.0001 0.3499 0.5275 0.1024 13 
TBX21 0.0011 0.0001 0.3869 0.6571 0 13 
PARP9 0.0011 0.0001 0.4825 0.7692 0.5707 13 
CCL2 0.0018 0.0002 0.2731 0.5128 0.3962 13 
ADA 0.0026 0.0003 0.2518 0.419 0.0915 13 
CDH1 0.0163 0.0027 0.2264 0.3333 0.0915 13 
MYOCD 0.0243 0.0046 0.1901 0.281 0 13 
IL22 0.0297 0.0061 0.1948 0.2794 0 13 
NPPA 0.0399 0.0088 0.1941 0.2667 0 13 
AGTR1 0.0453 0.0108 0.1749 0.2398 0.2567 13 
FBN1 0.0011 0.0001 0.4 0.6484 0.5883 12 
HDAC6 0.0011 0.0001 0.2858 0.4872 0.1044 12 
IL25 0.0011 0.0001 0.2872 0.5128 0 12 
DDR1 0.0018 0.0002 0.3401 0.5909 0.1206 12 
TREM1 0.0026 0.0003 0.2255 0.4066 0.2824 12 
ITGB1 0.0033 0.0004 0.273 0.4359 0.2205 12 
HMOX1 0.0083 0.0012 0.2265 0.3974 0.3442 12 
GDF9 0.0192 0.0034 0.2036 0.2941 0.136 12 
CAT 0.0215 0.0039 0.1834 0.2952 0.0382 12 
HOXB7 0.0266 0.0052 0.221 0.3182 0.0449 12 
CD86 0.0011 0.0001 0.3673 0.6818 0.5284 11 
PTAFR 0.0033 0.0004 0.2631 0.4909 0.2883 11 
ICAM1 0.004 0.0005 0.2448 0.4103 0.2991 11 
HIVEP1 0.0066 0.0009 0.239 0.35 0.0584 11 
NPPB 0.0228 0.0042 0.1772 0.3077 0 11 
LDLR 0.025 0.0048 0.2386 0.3636 0.1969 11 
TNFSF13B 0.0297 0.0061 0.1679 0.2952 0.3165 11 
PIAS1 0.042 0.0095 0.2098 0.3091 0.0469 11 
PF4 0.0011 0.0001 0.4154 0.7778 0 10 
NLRP12 0.0011 0.0001 0.4782 0.5636 0 10 
TICAM1 0.0011 0.0001 0.4281 0.6444 0.1982 10 
HMGB1 0.0026 0.0003 0.282 0.4848 0.0788 10 
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C3 0.0072 0.001 0.2785 0.4182 0.2492 10 
BAK1 0.0237 0.0044 0.2121 0.3205 0.2372 10 
PRKCB 0.0239 0.0045 0.2223 0.3485 0 10 
OLR1 0.0011 0.0001 0.4369 0.8056 0.5582 9 
AIMP1 0.0011 0.0001 0.4375 0.75 0 9 
IGF2BP1 0.0011 0.0001 0.5706 0.8 0.0748 9 
NPR1 0.0018 0.0002 0.3367 0.5636 0.1101 9 
NT5E 0.0018 0.0002 0.3068 0.5333 0.362 9 
DDX58 0.0046 0.0006 0.3512 0.5278 0.4749 9 
HRH2 0.0083 0.0012 0.2851 0.5 0 9 
CXCL3 0.0159 0.0026 0.2454 0.4167 0.2109 9 
TRAF6 0.0239 0.0045 0.2157 0.3889 0.0786 9 
FOXF1 0.0286 0.0057 0.2249 0.3333 0.1901 9 
SMAD1 0.0407 0.009 0.2633 0.3333 0.0894 9 
S1PR1 0.0456 0.0112 0.1915 0.3091 0 9 
PRKCZ 0.0493 0.0126 0.2288 0.3111 0.1228 9 
TSC22D3 0.0011 0.0001 0.4354 0.75 0.094 8 
PPBP 0.0011 0.0001 0.4081 0.7143 0.278 8 
TNNI3 0.0011 0.0001 0.4634 0.8214 0.0579 8 
TRAF3IP2 0.0011 0.0001 0.3141 0.6429 0.0739 8 
SPIC 0.0011 0.0001 0.4684 0.75 0 8 
CBL 0.0018 0.0002 0.4775 0.6222 0.0572 8 
IFNAR1 0.0018 0.0002 0.3825 0.6786 0.2189 8 
PLG 0.0059 0.0008 0.2737 0.5357 0 8 
VCAN 0.0094 0.0014 0.2565 0.5 0.4753 8 
TFDP1 0.0123 0.0019 0.2675 0.4444 0.2462 8 
HSF2 0.0187 0.0032 0.2125 0.3778 0.2117 8 
DUSP1 0.0278 0.0055 0.2218 0.3556 0.245 8 
HEY1 0.0364 0.0079 0.2458 0.3611 0.118 8 
ELF1 0.0011 0.0001 0.5876 0.9524 0.1427 7 
ABCB4 0.0026 0.0003 0.3895 0.5714 0 7 
FOSL1 0.0026 0.0003 0.3372 0.5556 0 7 
EPHB1 0.0033 0.0004 0.3184 0.5278 0.0401 7 
CXCL2 0.0088 0.0013 0.3083 0.5 0.3822 7 
BID 0.0105 0.0016 0.2986 0.5714 0.1931 7 
TIRAP 0.0123 0.0019 0.3934 0.5238 0 7 
IL23A 0.0133 0.0021 0.2495 0.4643 0.1135 7 
BARX1 0.0159 0.0026 0.2287 0.4167 0 7 
FASLG 0.0192 0.0034 0.2736 0.4762 0.1772 7 
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IDO1 0.0228 0.0042 0.2009 0.4286 0 7 
ILK 0.0259 0.005 0.2629 0.3455 0.1241 7 
FCGR2B 0.0291 0.0059 0.2715 0.4286 0.3921 7 
KNG1 0.0331 0.007 0.2186 0.3611 0 7 
BDKRB1 0.0431 0.0099 0.2367 0.3571 0.2655 7 
TNXB 0.0011 0.0001 0.8818 1 0.058 6 
DSP 0.0018 0.0002 0.4585 0.8 0.0541 6 
CASP8 0.0033 0.0004 0.3866 0.7333 0.0716 6 
INHBB 0.019 0.0033 0.2693 0.4167 0.0725 6 
RXRB 0.019 0.0033 0.2241 0.4286 0.0871 6 
TXN 0.0278 0.0055 0.243 0.4286 0.072 6 
RFX5 0.0282 0.0056 0.3977 0.4667 0.3275 6 
LILRB4 0.0291 0.0059 0.3095 0.4667 0.466 6 
S1PR2 0.03 0.0062 0.307 0.4667 0 6 
ZBTB7B 0.03 0.0062 0.3386 0.4667 0 6 
EREG 0.0417 0.0094 0.2208 0.381 0.2933 6 
NPC1 0.0417 0.0094 0.2289 0.3571 0 6 
IL10RA 0.0459 0.0114 0.255 0.381 0.4407 6 
IRF9 0.0488 0.0124 0.2424 0.4 0.2781 6 
PSMD4 0.0011 0.0001 0.4077 1 0.0567 5 
MAPKAPK2 0.0011 0.0001 0.411 0.9 0.0191 5 
IFNK 0.0011 0.0001 0.5843 0.9 0 5 
SMOC2 0.0011 0.0001 0.5815 1 0.1801 5 
PRKG1 0.0026 0.0003 0.4543 0.9 0.467 5 
PTGIR 0.0026 0.0003 0.3117 0.8 0 5 
PARP2 0.004 0.0005 0.369 0.6667 0.0627 5 
MED28 0.004 0.0005 0.4004 0.6667 0 5 
E2F8 0.0046 0.0006 0.3503 0.8 0.448 5 
FCER2 0.0053 0.0007 0.4035 0.6667 0 5 
TNFRSF8 0.0059 0.0008 0.3596 0.7 0 5 
ANXA2 0.0072 0.001 0.3253 0.6 0.2871 5 
RARRES3 0.0078 0.0011 0.4587 0.7 0.4302 5 
SFTPD 0.0083 0.0012 0.3168 0.6 0.0803 5 
MST1 0.0088 0.0013 0.324 0.7 0.2038 5 
F2RL1 0.015 0.0024 0.3132 0.6 0.0917 5 
SLPI 0.0156 0.0025 0.2585 0.6 0.1241 5 
LTBP4 0.0184 0.0031 0.2472 0.5333 0.1344 5 
TGFB1I1 0.0192 0.0034 0.2986 0.5333 0.3685 5 
DLX5 0.0196 0.0035 0.2702 0.5333 0.1014 5 
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FCGR2A 0.0313 0.0065 0.2602 0.4667 0.4464 5 
STAT2 0.0324 0.0068 0.3167 0.5 0.2525 5 
MMP13 0.0338 0.0072 0.2907 0.5 0.3257 5 
TRIM21 0.0359 0.0077 0.2568 0.5 0.2794 5 
HP 0.0453 0.0108 0.2559 0.4 0.1692 5 
GABPB1 0.0454 0.011 0.2047 0.4 0 5 
ABCA1 0.0474 0.0119 0.2596 0.381 0.1622 5 
ITGAV 0.0011 0.0001 0.6839 1 0.2752 4 
MBP 0.0011 0.0001 0.6479 1 0.1123 4 
DDR2 0.0011 0.0001 0.5943 1 0.4028 4 
ABCG1 0.0078 0.0011 0.4424 0.8333 0.1188 4 
TNFAIP3 0.0094 0.0014 0.3463 0.8333 0.4688 4 
LGI1 0.0105 0.0016 0.4602 0.8333 0.1187 4 
C5AR1 0.0123 0.0019 0.5863 0.8333 0.5999 4 
PON1 0.0159 0.0026 0.3832 0.6 0.1179 4 
AHRR 0.0159 0.0026 0.2525 0.6 0 4 
LBP 0.0184 0.0031 0.3223 0.6667 0.0716 4 
PLA2G10 0.0187 0.0032 0.299 0.6667 0.0612 4 
PTN 0.019 0.0033 0.2579 0.6 0.0574 4 
CBX4 0.019 0.0033 0.4649 0.6667 0 4 
CD200R1 0.0192 0.0034 0.3108 0.6667 0 4 
TANK 0.0196 0.0035 0.353 0.6667 0.0958 4 
DNASE2 0.0206 0.0037 0.3843 0.6667 0.19 4 
C1QA 0.021 0.0038 0.3002 0.6667 0.1886 4 
CASP10 0.021 0.0038 0.3528 0.6667 0.1002 4 
SELL 0.0218 0.004 0.3453 0.6667 0.3205 4 
MAVS 0.0218 0.004 0.372 0.6667 0 4 
B2M 0.0232 0.0043 0.444 0.6667 0.4819 4 
WNT10B 0.0239 0.0045 0.2961 0.6667 0 4 
LAT 0.0243 0.0046 0.3081 0.6667 0.1237 4 
RCAN1 0.0247 0.0047 0.2791 0.6667 0.2421 4 
ARRB2 0.0328 0.0069 0.301 0.5 0.1803 4 
SFTPA1 0.0338 0.0072 0.2646 0.5 0 4 
SCGB1A1 0.0362 0.0078 0.2891 0.5 0.0724 4 
CCR1 0.0382 0.0083 0.3042 0.5 0.4395 4 
EDNRA 0.0385 0.0084 0.3741 0.5 0.3249 4 
SPIB 0.0388 0.0085 0.2963 0.5 0 4 
NOD2 0.0409 0.0091 0.2624 0.5 0.2456 4 
FLT3LG 0.0417 0.0094 0.2545 0.5 0 4 
93 
 
IL27RA 0.0448 0.0106 0.2917 0.5 0.0863 4 
FABP4 0.0458 0.0113 0.2735 0.5 0.2879 4 
FYN 0.0458 0.0113 0.3026 0.5 0.1694 4 
LTB4R 0.0484 0.0122 0.2208 0.5 0 4 
CFB 0.0487 0.0123 0.2938 0.4 0.3246 4 
PBX1 0.0488 0.0124 0.2667 0.4 0.1543 4 
TIMP1 0.05 0.0128 0.2648 0.4 0.2038 4 
CBFB 0.0011 0.0001 0.9446 1 0.0961 3 
DES 0.0011 0.0001 0.4602 1 0.1004 3 
DRD1 0.0011 0.0001 0.7372 1 0 3 
EPHX2 0.0011 0.0001 0.3956 1 0.1719 3 
GABBR1 0.0011 0.0001 0.3313 1 0.1287 3 
GCLC 0.0011 0.0001 0.5474 1 0.0791 3 
GCLM 0.0011 0.0001 0.5474 1 0.0468 3 
GNRH2 0.0011 0.0001 0.396 1 0 3 
HSPA1A 0.0011 0.0001 0.495 1 0.1519 3 
IL13RA2 0.0011 0.0001 0.4086 1 0.0599 3 
JAG2 0.0011 0.0001 0.3767 1 0.2345 3 
LTB 0.0011 0.0001 0.5664 1 0.4006 3 
MSR1 0.0011 0.0001 0.3951 1 0.3965 3 
GADD45B 0.0011 0.0001 0.5926 1 0.4372 3 
PRTN3 0.0011 0.0001 0.4449 1 0 3 
TCF7 0.0011 0.0001 0.3491 1 0.0571 3 
UBA7 0.0011 0.0001 0.6578 1 0 3 
UXT 0.0011 0.0001 0.4761 1 0.0956 3 
RIPK2 0.0011 0.0001 0.6284 1 0.2921 3 
TNFRSF6B 0.0011 0.0001 0.5085 1 0 3 
ZBED1 0.0011 0.0001 0.3991 1 0 3 
BACH2 0.0011 0.0001 0.3644 1 0 3 
NLRP3 0.0011 0.0001 0.5498 1 0.6298 3 
LSS 0.0422 0.0096 0.3034 0.6667 0.1865 3 
RGS2 0.0431 0.0099 0.2664 0.5 0.2105 3 
LRP1 0.0437 0.0101 0.3483 0.5 0 3 
MSX1 0.0439 0.0102 0.2214 0.5 0.0819 3 
CD69 0.0442 0.0103 0.2746 0.5 0.4503 3 
HEYL 0.0445 0.0104 0.2454 0.6667 0 3 
ITGA5 0.0448 0.0106 0.3309 0.6667 0.5833 3 
MMP7 0.0448 0.0106 0.324 0.6667 0.1766 3 
SULT1E1 0.0448 0.0106 0.2764 0.6667 0.0688 3 
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AGA 0.0453 0.0109 0.2718 0.5 0 3 
TNIP3 0.0453 0.0109 0.3881 0.6667 0.3482 3 
NCF1 0.0453 0.0109 0.2966 0.6667 0.3854 3 
RTKN 0.0454 0.011 0.2728 0.5 0.0705 3 
ING4 0.0454 0.011 0.2578 0.5 0.0801 3 
HSPG2 0.0454 0.0111 0.2216 0.6667 0.1914 3 
MMP9 0.0454 0.0111 0.3104 0.6667 0.3037 3 
LRRC8C 0.0454 0.0111 0.2664 0.5 0 3 
KDM1A 0.0459 0.0114 0.3209 0.6667 0 3 
SLC4A1 0.0462 0.0115 0.4954 0.5 0 3 
FGA 0.0493 0.0126 0.388 0.6667 0 3 
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APPENDIX C 
Regulator FDR p-value 
ave. corr. 
(regulatees) fraction 
ave. corr. 
(regulator-
regulatees) 
# of 
coherent 
regulatees 
TGFB1 0.0014 0.0001 0.1242 0.0942 0.0885 723 
IFNG 0.0014 0.0001 0.1365 0.1246 0.238 624 
MYC 0.0014 0.0001 0.1475 0.1406 0.1623 439 
IL6 0.0014 0.0001 0.1289 0.1084 0.1104 370 
IL4 0.0014 0.0001 0.1313 0.112 0.0863 333 
IL13 0.0084 0.0007 0.1255 0.1004 0.0724 302 
MYCN 0.0014 0.0001 0.1749 0.1848 0.0972 272 
IL1A 0.0466 0.0056 0.1244 0.097 0.0746 262 
ERBB2 0.0027 0.0002 0.1343 0.1133 0.0535 253 
IFNB1 0.0014 0.0001 0.1449 0.1394 0.0911 251 
IL10 0.0014 0.0001 0.1351 0.1186 0.1336 249 
CDKN1A 0.0014 0.0001 0.1896 0.2396 0.084 234 
F2 0.004 0.0003 0.1351 0.1148 0.0704 233 
IL2 0.0014 0.0001 0.1508 0.1561 0.0807 205 
CCND1 0.0014 0.0001 0.1454 0.1388 0.2025 204 
VEGFA 0.0014 0.0001 0.1427 0.1271 0.1572 189 
MAPK1 0.0014 0.0001 0.1394 0.1291 0.1062 183 
TNFSF11 0.0014 0.0001 0.1493 0.1511 0.076 166 
BRCA1 0.0014 0.0001 0.1443 0.141 0.251 162 
CDKN2A 0.0014 0.0001 0.1523 0.1541 0.0842 158 
PRL 0.0084 0.0007 0.139 0.1202 0.0822 155 
DMD 0.0014 0.0001 0.1483 0.1456 0.097 153 
IRF7 0.0014 0.0001 0.172 0.2045 0.2636 142 
FOS 0.0493 0.006 0.1331 0.1113 0.1802 133 
E2F4 0.0014 0.0001 0.1801 0.2227 0.1615 130 
IFNA2 0.0014 0.0001 0.1893 0.2487 0.0788 128 
E2F1 0.0027 0.0002 0.1427 0.1382 0.2102 127 
CSF1 0.0014 0.0001 0.1395 0.1307 0.1579 125 
XBP1 0.0376 0.0043 0.1382 0.1176 0.1923 124 
IKBKB 0.0014 0.0001 0.1434 0.1402 0.1011 121 
EDN1 0.0014 0.0001 0.1581 0.1692 0.0985 116 
SOCS3 0.0051 0.0004 0.1413 0.1355 0.1739 113 
EP300 0.0073 0.0006 0.14 0.1291 0.0842 110 
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FGF1 0.0204 0.002 0.134 0.1223 0.0909 109 
HMGA1 0.0499 0.0061 0.1349 0.1162 0.1676 109 
CHUK 0.0014 0.0001 0.155 0.1661 0.1245 105 
MAPK8 0.0169 0.0016 0.136 0.1241 0.0779 96 
STAT1 0.0014 0.0001 0.1803 0.231 0.3404 93 
NCOR1 0.0014 0.0001 0.1605 0.1717 0.0867 93 
THAP1 0.0014 0.0001 0.2674 0.4077 0.0747 87 
DYSF 0.0014 0.0001 0.1566 0.1667 0.2287 84 
STAT6 0.0014 0.0001 0.1543 0.1583 0.1399 80 
CD40LG 0.0051 0.0004 0.1482 0.148 0.1277 79 
TLR4 0.0336 0.0037 0.1356 0.1247 0.2064 79 
ZBTB16 0.0014 0.0001 0.1721 0.215 0.0855 78 
ROCK1 0.026 0.0027 0.1442 0.1321 0.1128 77 
JAK1 0.0062 0.0005 0.1467 0.1445 0.0989 75 
JUN 0.032 0.0035 0.1383 0.1283 0.2185 74 
IFNA1 0.0014 0.0001 0.1824 0.2283 0.0874 73 
IKBKG 0.0027 0.0002 0.1495 0.156 0.0764 71 
IL1RN 0.0014 0.0001 0.1812 0.2302 0.1523 67 
SPI1 0.0014 0.0001 0.1579 0.1757 0.2008 66 
PTH 0.0362 0.0041 0.1451 0.1326 0.071 65 
IL15 0.0299 0.0032 0.1472 0.1396 0.2728 64 
TGFBR1 0.0236 0.0024 0.1495 0.1425 0.1207 62 
IRF8 0.0105 0.0009 0.1469 0.1497 0.1062 61 
ERBB3 0.0178 0.0017 0.1496 0.1461 0.0669 57 
RB1 0.0014 0.0001 0.1744 0.2112 0.1264 56 
VHL 0.0094 0.0008 0.1474 0.158 0.0973 56 
IL29 0.0014 0.0001 0.3501 0.5966 0.1094 53 
IRF1 0.0051 0.0004 0.161 0.1782 0.3162 52 
FAS 0.0014 0.0001 0.2081 0.277 0.1505 51 
SMAD7 0.0134 0.0012 0.1631 0.1598 0.2424 51 
CCL5 0.0073 0.0006 0.1621 0.1829 0.2596 50 
IL27 0.0014 0.0001 0.1894 0.2348 0.1012 48 
FADD 0.0362 0.0041 0.1539 0.1494 0.082 48 
S100B 0.0014 0.0001 0.1797 0.2257 0.0838 47 
ITGB6 0.0014 0.0001 0.1879 0.2498 0.0923 46 
TGFB3 0.0014 0.0001 0.1992 0.2513 0.1224 45 
BNIP3L 0.0014 0.0001 0.1722 0.2044 0.1035 44 
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TNFSF10 0.0014 0.0001 0.1775 0.2029 0.298 43 
TNC 0.0027 0.0002 0.1905 0.2251 0.2042 43 
APOE 0.0014 0.0001 0.1806 0.2199 0.3067 41 
MAP2K1 0.0027 0.0002 0.1642 0.1967 0.0952 41 
TNFSF12 0.0027 0.0002 0.1648 0.1998 0.2424 39 
IFNA13 0.0014 0.0001 0.1888 0.2387 0 38 
RBL2 0.0124 0.0011 0.1578 0.1839 0.13 35 
CYP2C18 0.0294 0.0031 0.1592 0.1787 0.0623 33 
MAP3K7 0.0014 0.0001 0.1898 0.2492 0.1012 30 
SPDEF 0.0014 0.0001 0.2372 0.3455 0.0598 30 
MYD88 0.0169 0.0016 0.1677 0.1849 0.1536 29 
HOXD3 0.0312 0.0034 0.1505 0.1603 0.0679 29 
MAP3K1 0.0204 0.002 0.1568 0.1857 0.1201 28 
GPX1 0.0027 0.0002 0.1887 0.2359 0.274 27 
HSF1 0.0062 0.0005 0.1755 0.2238 0.1897 27 
ATM 0.0014 0.0001 0.217 0.2874 0.1025 26 
SOCS1 0.0014 0.0001 0.1938 0.2828 0.0826 25 
S100A6 0.0299 0.0032 0.1824 0.1994 0.1827 25 
LTA 0.0394 0.0046 0.1576 0.1828 0.1517 25 
FOXM1 0.0139 0.0013 0.1659 0.1978 0.3062 23 
RBL1 0.0014 0.0001 0.247 0.4021 0.2387 22 
TAB1 0.0014 0.0001 0.2218 0.3167 0.0741 22 
CCL13 0.0196 0.0019 0.1768 0.2116 0.1846 21 
CCR5 0.0245 0.0025 0.1755 0.2101 0.3323 21 
GAPDH 0.0014 0.0001 0.222 0.3033 0.1692 19 
IL12B 0.0094 0.0008 0.2066 0.249 0.0743 19 
CORT 0.0113 0.001 0.2005 0.2391 0.097 19 
F7 0.0305 0.0033 0.1748 0.2065 0.0784 18 
PRKCD 0.0358 0.004 0.1596 0.1931 0.0875 18 
BLK 0.0437 0.0052 0.1595 0.2016 0.1642 18 
SEMA7A 0.0139 0.0013 0.2185 0.2579 0.0743 17 
ALDH1A2 0.0014 0.0001 0.2892 0.3853 0.0975 16 
IL17F 0.0051 0.0004 0.2474 0.3235 0.0628 16 
PARP9 0.0014 0.0001 0.3443 0.6 0.3841 15 
F2R 0.004 0.0003 0.2317 0.3041 0.24 15 
GRP 0.0362 0.0041 0.1911 0.2353 0.0556 15 
TBK1 0.0014 0.0001 0.2776 0.4667 0.0711 14 
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TBX21 0.0014 0.0001 0.2755 0.4035 0.3648 14 
E2F2 0.0139 0.0013 0.2057 0.2579 0.2276 14 
E2F3 0.0196 0.0019 0.2007 0.2573 0.0737 14 
FBN1 0.0014 0.0001 0.3882 0.6154 0.5149 13 
TRIM28 0.0236 0.0024 0.2146 0.2667 0.2096 13 
HIVEP1 0.0051 0.0004 0.2308 0.3309 0.0559 12 
FOXE1 0.0376 0.0043 0.1627 0.2476 0.0719 12 
HDAC6 0.0014 0.0001 0.2692 0.4505 0.0799 11 
TICAM1 0.0014 0.0001 0.3041 0.4848 0.0619 11 
GABPA 0.0139 0.0013 0.1879 0.2647 0.1213 11 
IL17RA 0.0299 0.0032 0.1945 0.2571 0.2073 11 
PTAFR 0.0014 0.0001 0.3045 0.4909 0.298 10 
NLRP12 0.0014 0.0001 0.291 0.4182 0.1362 10 
CD86 0.0351 0.0039 0.1999 0.2821 0.1688 10 
CBL 0.0014 0.0001 0.3898 0.6667 0.113 9 
HSF2 0.0014 0.0001 0.2943 0.5636 0.1572 9 
IGF2BP1 0.0014 0.0001 0.4454 0.6182 0.0708 9 
MXI1 0.0027 0.0002 0.2921 0.5455 0.1856 9 
CXCL2 0.0105 0.0009 0.2587 0.4222 0.1751 9 
PEX5L 0.0113 0.001 0.269 0.4 0.0554 9 
CEACAM1 0.0252 0.0026 0.2163 0.3091 0.0665 9 
S1PR1 0.0391 0.0045 0.1872 0.2692 0.1001 9 
ACVR1C 0.0394 0.0046 0.1885 0.2727 0.1475 9 
NPC1 0.0213 0.0021 0.2556 0.3611 0.41 8 
HRH2 0.0351 0.0039 0.2102 0.3111 0.0429 8 
TFDP1 0.0431 0.0051 0.2108 0.3111 0.3236 8 
INHBB 0.0014 0.0001 0.349 0.5556 0.2109 7 
EPHB1 0.0027 0.0002 0.2979 0.5 0.1241 7 
IFNAR1 0.0027 0.0002 0.3115 0.5278 0.2966 7 
BID 0.0094 0.0008 0.3151 0.5238 0.13 7 
IFNGR1 0.0236 0.0024 0.2176 0.3333 0.237 7 
ZBTB7B 0.0236 0.0024 0.312 0.3929 0.1176 7 
IL10RA 0.0394 0.0046 0.2364 0.381 0.1994 7 
FOSL1 0.0409 0.0048 0.2183 0.3333 0.1899 7 
SMOC2 0.0014 0.0001 0.5275 1 0.2699 6 
ACVRL1 0.0113 0.001 0.3285 0.5238 0.3632 6 
TNNI3 0.0134 0.0012 0.295 0.3889 0.13 6 
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DSP 0.0188 0.0018 0.3519 0.4762 0.1475 6 
RFX5 0.0232 0.0023 0.3405 0.4667 0.3185 6 
DDX58 0.0278 0.0029 0.2534 0.3333 0.384 6 
ABCG1 0.0443 0.0053 0.2576 0.4 0.1398 6 
LRP1 0.0014 0.0001 0.5121 1 0.0483 5 
GDF15 0.0014 0.0001 0.531 1 0.1111 5 
IFNK 0.0014 0.0001 0.4998 1 0.0474 5 
TNXB 0.0051 0.0004 0.5586 0.6667 0.0398 5 
FLT1 0.0139 0.0013 0.351 0.5333 0.06 5 
USP18 0.0139 0.0013 0.2906 0.5333 0.3677 5 
FCGR2B 0.0286 0.003 0.2672 0.4667 0.0915 5 
ANXA2 0.0305 0.0033 0.2935 0.4667 0.3118 5 
CBFB 0.0014 0.0001 0.584 1 0.1214 4 
C1QA 0.0073 0.0006 0.3026 0.8333 0.1332 4 
ITGAV 0.0113 0.001 0.4178 0.8333 0.5506 4 
E2F8 0.0139 0.0013 0.2867 0.6 0.38 4 
RCAN1 0.0252 0.0026 0.3187 0.6667 0.1061 4 
ANPEP 0.0014 0.0001 0.4959 1 0.0727 3 
CKS1B 0.0014 0.0001 0.644 1 0.5824 3 
CKS2 0.0014 0.0001 0.644 1 0.5994 3 
GCLC 0.0014 0.0001 0.5574 1 0.0698 3 
GCLM 0.0014 0.0001 0.5574 1 0.134 3 
GADD45B 0.0014 0.0001 0.3908 1 0.0054 3 
PTPRC 0.0014 0.0001 0.5627 1 0.078 3 
TCF7 0.0014 0.0001 0.4494 1 0.43 3 
UBA7 0.0014 0.0001 0.445 1 0.4173 3 
ZBED1 0.0014 0.0001 0.8627 1 0.1592 3 
PLAA 0.0014 0.0001 0.3908 1 0.0423 3 
MSC 0.0431 0.0051 0.3339 0.5 0.0852 3 
UXT 0.0472 0.0057 0.3355 0.6667 0.111 3 
FGA 0.0487 0.0059 0.3133 0.6667 0.0271 3 
ADORA2B 0.0014 0.0001 0.3253 1 0.0202 2 
AMELX 0.0014 0.0001 0.3022 1 0.0789 2 
CASP3 0.0014 0.0001 0.6509 1 0.1038 2 
CASQ2 0.0014 0.0001 0.2899 1 0.3478 2 
CMA1 0.0014 0.0001 0.8021 1 0.0651 2 
COL2A1 0.0014 0.0001 0.8021 1 0.281 2 
100 
 
COL4A3 0.0014 0.0001 0.8042 1 0.0216 2 
CSK 0.0014 0.0001 0.3253 1 0.1208 2 
CYP7A1 0.0014 0.0001 0.3342 1 0.0382 2 
LPAR1 0.0014 0.0001 0.3305 1 0.3737 2 
EMD 0.0014 0.0001 0.3614 1 0.0415 2 
FCGR3A 0.0014 0.0001 0.6148 1 0.508 2 
G6PC 0.0014 0.0001 0.4559 1 0.1199 2 
HIST1H1C 0.0014 0.0001 0.905 1 0.0473 2 
HAS2 0.0014 0.0001 0.3028 1 0.2549 2 
CFH 0.0014 0.0001 0.2783 1 0.1831 2 
IK 0.0014 0.0001 0.3344 1 0.0554 2 
IL12RB1 0.0014 0.0001 0.4116 1 0.1899 2 
NMB 0.0014 0.0001 0.5762 1 0.0703 2 
PCBP2 0.0014 0.0001 0.6483 1 0.0498 2 
PLP1 0.0014 0.0001 0.4066 1 0.1574 2 
HTRA1 0.0014 0.0001 0.4329 1 0.1983 2 
PTPRG 0.0014 0.0001 0.306 1 0.1091 2 
CXCL6 0.0014 0.0001 0.3253 1 0.236 2 
TRPM2 0.0014 0.0001 0.5403 1 0.1315 2 
TXK 0.0014 0.0001 0.8001 1 0.295 2 
EOMES 0.0014 0.0001 0.6204 1 0.6593 2 
IRS4 0.0014 0.0001 0.3355 1 0.1116 2 
RPS6KA4 0.0014 0.0001 0.5762 1 0.0689 2 
F2RL3 0.0014 0.0001 0.6558 1 0.051 2 
RPS6KA5 0.0014 0.0001 0.5762 1 0.0487 2 
BCL2L11 0.0014 0.0001 0.5626 1 0.1119 2 
AGPAT2 0.0014 0.0001 0.277 1 0.2332 2 
WDR5 0.0014 0.0001 0.2838 1 0.0597 2 
CD160 0.0014 0.0001 0.5762 1 0.154 2 
TPSD1 0.0014 0.0001 0.497 1 0.0743 2 
MYOZ2 0.0014 0.0001 0.2872 1 0.1113 2 
IKZF4 0.0014 0.0001 0.618 1 0.1766 2 
MARCKSL1 0.0014 0.0001 0.2899 1 0.1275 2 
MCPH1 0.0014 0.0001 0.7106 1 0.1196 2 
CMIP 0.0014 0.0001 0.3129 1 0.3021 2 
TWIST2 0.0014 0.0001 0.3253 1 0.3092 2 
VSX2 0.0014 0.0001 0.5959 1 0 2 
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APPENDIX D 
Regulato
r FDR 
p-
value 
ave. corr. 
(regulatee
s) 
fractio
n 
ave. corr. 
(regulator
-
regulatee
s) 
# of 
coherent 
regulate
es 
Found with 
whole KB 
HIF1A 0.0013 0.0001 0.1407 0.1442 0.1381 149 N 
TGFB1 0.0013 0.0001 0.1529 0.1697 0.2343 111 Y 
IL13 0.0013 0.0001 0.1729 0.1954 0 80 Y 
EP300 0.0013 0.0001 0.1538 0.1681 0.0781 75 Y 
THAP1 0.0013 0.0001 0.2848 0.4625 0.0959 75 Y 
E2F4 0.0013 0.0001 0.1618 0.1852 0.0733 73 Y 
CCND1 0.0013 0.0001 0.1671 0.1999 0.1699 58 N 
MYCN 0.0013 0.0001 0.1916 0.2482 0.1009 43 Y 
TLR4 0.0013 0.0001 0.1721 0.1976 0.3036 42 Y 
STAT1 0.0013 0.0001 0.262 0.4228 0.3932 41 Y 
IFNA13 0.0013 0.0001 0.2582 0.4153 0 38 Y 
JUN 0.0013 0.0001 0.1989 0.2613 0.0942 32 Y 
CHUK 0.0013 0.0001 0.2197 0.339 0.0724 31 Y 
SMAD3 0.0013 0.0001 0.183 0.2222 0.0853 31 Y 
CD40LG 0.0013 0.0001 0.2379 0.3977 0 29 Y 
TGFB2 0.0013 0.0001 0.2395 0.3563 0.0659 26 Y 
SPI1 0.0013 0.0001 0.3665 0.547 0.5267 24 Y 
IL10 0.0013 0.0001 0.259 0.3953 0.3306 19 Y 
IFNB1 0.0013 0.0001 0.2366 0.368 0 17 Y 
LPL 0.0013 0.0001 0.2468 0.3762 0.1209 16 Y 
CSF2RB 0.0013 0.0001 0.2533 0.3743 0 15 Y 
ABCB1 0.0013 0.0001 0.2812 0.3737 0.1905 15 Y 
IL12B 0.0013 0.0001 0.2469 0.3971 0 13 Y 
IL18 0.0013 0.0001 0.2503 0.4381 0.2372 13 Y 
ZNF175 0.0013 0.0001 0.4129 0.5604 0.1094 13 Y 
E2F3 0.0013 0.0001 0.2646 0.4909 0.1863 11 Y 
CTGF 0.0013 0.0001 0.4258 0.6444 0.4182 10 Y 
E2F2 0.0013 0.0001 0.2548 0.4545 0.3182 10 Y 
IFNA1 0.0013 0.0001 0.2559 0.4545 0 10 Y 
TBX21 0.0013 0.0001 0.3759 0.6 0 9 Y 
THBS1 0.0013 0.0001 0.3112 0.6429 0.3813 8 Y 
TSC22D3 0.0013 0.0001 0.397 0.7143 0.1041 7 Y 
IL25 0.0013 0.0001 0.3314 0.6667 0 7 Y 
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MYOCD 0.0013 0.0001 0.5027 0.9048 0 7 Y 
TNXB 0.0013 0.0001 0.8818 1 0.058 6 Y 
PRKG1 0.0013 0.0001 0.4543 0.9 0.467 5 Y 
ELF1 0.0013 0.0001 0.701 1 0.1731 4 Y 
CCL13 0.0013 0.0001 0.4227 1 0.1349 4 Y 
TLR2 0.0013 0.0001 0.494 1 0.5222 4 Y 
SCARB1 0.0013 0.0001 0.3654 1 0.0638 3 N 
IRF8 0.0013 0.0001 0.516 1 0.6405 3 Y 
MBP 0.0013 0.0001 0.7215 1 0.1289 3 Y 
MYD88 0.0013 0.0001 0.4956 1 0.199 3 Y 
PTN 0.0013 0.0001 0.4264 1 0.0659 3 Y 
XDH 0.0013 0.0001 0.3586 1 0.1566 3 Y 
CALCB 0.0013 0.0001 0.7026 1 0 2 N 
ERBB3 0.0013 0.0001 0.67 1 0.0291 2 Y 
ERBB4 0.0013 0.0001 0.67 1 0.1921 2 Y 
F7 0.0013 0.0001 0.8118 1 0 2 Y 
FLT1 0.0013 0.0001 0.3567 1 0.2615 2 N 
HOXB7 0.0013 0.0001 0.6509 1 0.0349 2 Y 
ITGA5 0.0013 0.0001 0.2736 1 0.6176 2 Y 
LDLR 0.0013 0.0001 0.4349 1 0.2112 2 Y 
NFKBIA 0.0013 0.0001 0.3253 1 0.348 2 Y 
NRAS 0.0013 0.0001 0.4514 1 0.1129 2 N 
SERPINE1 0.0013 0.0001 0.3655 1 0.6957 2 N 
PTGIR 0.0013 0.0001 0.312 1 0 2 Y 
THRB 0.0013 0.0001 0.4044 1 0.0509 2 N 
FOSL1 0.0013 0.0001 0.2736 1 0 2 Y 
CDKN1A 0.0023 0.0002 0.1492 0.155 0.1159 104 Y 
SRC 0.0023 0.0002 0.1719 0.2074 0.1101 45 Y 
IL6 0.0023 0.0002 0.1646 0.2185 0.2013 42 Y 
NRF1 0.0023 0.0002 0.1762 0.2141 0 40 Y 
IL4 0.0023 0.0002 0.1802 0.2282 0 33 Y 
LTA 0.0023 0.0002 0.2255 0.3684 0 15 Y 
RB1 0.0023 0.0002 0.2011 0.3203 0.1474 13 Y 
CD40 0.0023 0.0002 0.3043 0.5556 0.2403 9 Y 
FAS 0.0023 0.0002 0.2984 0.5333 0.3199 8 Y 
SPIC 0.0023 0.0002 0.4684 0.75 0 8 Y 
HOXD3 0.0032 0.0003 0.1856 0.2371 0.1139 31 Y 
HIVEP1 0.0032 0.0003 0.257 0.4 0.0605 11 Y 
HMOX1 0.0032 0.0003 0.2907 0.5556 0.3727 8 Y 
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FCGR2A 0.0032 0.0003 0.3683 0.7 0.5194 5 Y 
DYSF 0.0041 0.0004 0.1515 0.1644 0.1377 73 Y 
TAF4 0.0041 0.0004 0.2142 0.3333 0.1358 11 N 
PIAS1 0.0041 0.0004 0.3114 0.6667 0.0665 6 Y 
S100B 0.0049 0.0005 0.1737 0.2011 0.1289 34 Y 
CASP8 0.0049 0.0005 0.3896 0.8 0.0726 5 Y 
IL12A 0.0049 0.0005 0.3065 0.7 0.2182 5 Y 
E2F8 0.0049 0.0005 0.3305 0.8333 0.4369 4 Y 
IL5 0.0058 0.0006 0.3222 0.6 0 4 Y 
IFNA2 0.0065 0.0007 0.2511 0.2917 0 11 Y 
IL21 0.0065 0.0007 0.2935 0.5 0 8 Y 
FN1 0.0065 0.0007 0.3018 0.5 0.5166 7 N 
TLR3 0.0082 0.0009 0.3189 0.5238 0.3669 6 Y 
LIPG 0.0089 0.001 0.1905 0.2619 0.1586 16 Y 
ANXA2 0.0089 0.001 0.3253 0.6 0.2871 5 Y 
BARX1 0.0096 0.0011 0.2287 0.4167 0 7 Y 
CD200 0.0096 0.0011 0.3108 0.6667 0.1463 4 N 
RUNX2 0.0103 0.0012 0.2803 0.4643 0.4012 6 N 
FADD 0.0103 0.0012 0.3211 0.6 0.0721 5 Y 
AHR 0.011 0.0013 0.3503 0.4762 0.1746 5 N 
IL1B 0.0117 0.0014 0.1467 0.1584 0.2313 53 Y 
LEP 0.0131 0.0016 0.1413 0.1393 0 74 N 
SMAD4 0.0131 0.0016 0.1955 0.2745 0.0893 16 Y 
PIM1 0.0138 0.0017 0.2639 0.4762 0.2291 5 N 
GABPA 0.0143 0.0018 0.2288 0.3889 0.0842 9 N 
PTAFR 0.0143 0.0018 0.3062 0.5333 0.2799 5 Y 
CSF2 0.0157 0.0021 0.1484 0.1454 0 63 Y 
CD34 0.0157 0.0021 0.1675 0.209 0.1642 24 Y 
ILK 0.0157 0.0021 0.2715 0.3889 0.128 6 Y 
DDX58 0.0157 0.002 0.3862 0.6667 0.469 4 Y 
OLR1 0.0157 0.0021 0.3848 0.6667 0.4439 4 Y 
PRRX1 0.0157 0.0021 0.3381 0.6667 0.522 4 N 
CASP10 0.0167 0.0023 0.3528 0.6667 0.1002 4 Y 
HMGA1 0.0167 0.0023 0.2474 0.6667 0.081 4 N 
CD200R1 0.0167 0.0023 0.3108 0.6667 0 4 Y 
DLX5 0.0173 0.0024 0.2702 0.4667 0.1014 5 Y 
MSX2 0.0178 0.0025 0.2515 0.3929 0.2244 6 N 
RHOA 0.0189 0.0027 0.1442 0.1497 0.1293 53 N 
APOE 0.0189 0.0027 0.3483 0.4286 0.3621 7 Y 
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HNRNPK 0.0193 0.0028 0.317 0.4286 0 5 N 
NOS2 0.0193 0.0028 0.2793 0.5 0 4 N 
PRKCB 0.0196 0.0029 0.2284 0.4286 0 6 Y 
CCR2 0.0196 0.0029 0.2653 0.4667 0.331 5 Y 
JAK1 0.0213 0.0032 0.1483 0.1433 0.1727 61 N 
PDGFB 0.0213 0.0032 0.1971 0.2574 0.2283 13 Y 
RFX5 0.0224 0.0034 0.3977 0.4667 0.3275 6 Y 
PARP1 0.0242 0.0037 0.2497 0.5 0.1925 4 N 
PTGS2 0.0253 0.004 0.1376 0.1408 0.1512 57 Y 
S1PR1 0.0253 0.004 0.1915 0.3091 0 9 Y 
FCGR1A 0.0253 0.0039 0.2761 0.5 0.4286 4 N 
IRF1 0.0253 0.004 0.3039 0.5 0.4653 4 Y 
HRH2 0.0257 0.0041 0.2575 0.4667 0 6 Y 
ATF2 0.0261 0.0042 0.1853 0.2571 0.0779 11 N 
TNFSF10 0.0263 0.0043 0.1846 0.2692 0.2691 9 Y 
HSF2 0.0263 0.0043 0.2125 0.3333 0.2117 8 Y 
KLF2 0.0267 0.0044 0.2006 0.2821 0.2907 10 Y 
E2F1 0.0275 0.0046 0.1392 0.1344 0.198 74 Y 
HOXA13 0.0275 0.0046 0.1418 0.1513 0 48 N 
IL10RA 0.0279 0.0047 0.3094 0.5 0.4879 4 Y 
PPARGC1
A 0.0304 0.0052 0.1534 0.165 0.0635 33 N 
GLI2 0.0304 0.0052 0.2832 0.5 0.164 4 N 
FOXP3 0.0309 0.0054 0.1676 0.2035 0 13 Y 
EDNRA 0.0309 0.0054 0.3741 0.5 0.3249 4 Y 
AHRR 0.0309 0.0054 0.2525 0.5 0 4 Y 
IRF9 0.0312 0.0055 0.2424 0.4 0.2781 6 Y 
CXCL2 0.0313 0.0056 0.2688 0.381 0.3839 6 Y 
CCL2 0.0313 0.0056 0.2608 0.5 0.3994 4 Y 
CBS 0.0322 0.0058 0.2461 0.381 0.0381 6 N 
ING4 0.0331 0.006 0.2578 0.5 0.0801 3 Y 
CXCL3 0.0334 0.0061 0.2034 0.3571 0.2002 8 Y 
FHL2 0.0343 0.0063 0.2648 0.5 0.1757 4 N 
AIF1 0.0351 0.0065 0.3262 0.6667 0.0657 3 N 
FGFR1 0.0362 0.0068 0.2557 0.4 0.1183 4 N 
MAPK10 0.0362 0.0068 0.2406 0.5 0.0968 4 N 
VEGFA 0.0365 0.0069 0.1507 0.1628 0.0968 37 Y 
TRIM28 0.0373 0.0071 0.205 0.2476 0.1972 12 N 
HBP1 0.0376 0.0072 0.1994 0.2527 0.1089 13 Y 
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RAC1 0.0382 0.0077 0.1562 0.1714 0.0464 25 N 
PTH 0.0382 0.0076 0.2063 0.2727 0 8 Y 
CGB5 0.0382 0.0077 0.2488 0.3214 0 5 N 
GFI1 0.0382 0.0076 0.3233 0.6667 0 3 N 
TGIF1 0.0382 0.0076 0.3088 0.6667 0.0952 3 N 
ETV4 0.0382 0.0077 0.2617 0.5 0.0706 3 N 
SMAD1 0.0382 0.0077 0.218 0.5 0.1117 3 Y 
TFDP1 0.0382 0.0077 0.3476 0.6667 0.3058 3 Y 
ADRB1 0.0384 0.0078 0.1558 0.1651 0 31 N 
FGF1 0.0396 0.0081 0.1453 0.1585 0.2101 36 Y 
PXMP3 0.0399 0.0082 0.1707 0.2418 0 11 N 
FTH1 0.0406 0.0084 0.2025 0.2105 0.2294 12 N 
GABPB1 0.0432 0.009 0.1959 0.4 0 4 Y 
HP 0.0444 0.0093 0.2544 0.4 0.1587 4 Y 
BACH1 0.0446 0.0094 0.2104 0.3333 0.1254 5 N 
CEBPD 0.0448 0.0095 0.1724 0.2576 0.2326 10 N 
CSF1 0.045 0.0096 0.1649 0.1664 0.2421 28 Y 
ADRB2 0.0452 0.0097 0.1484 0.1564 0.1592 34 N 
SMARCA
4 0.0482 0.0104 0.1343 0.1223 0.1351 70 N 
NRIP1 0.0483 0.0105 0.1318 0.1123 0.0551 121 N 
ETS2 0.0485 0.0106 0.1737 0.2308 0.1097 10 N 
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APPENDIX E 
Gene 
Symbol 
Entrez 
ID 
Known 
drivers in 
breast 
cancer 
Drivers in 
other 
cancer 
types 
Candidate 
drivers 
identified by 
GWAS 
Involved in 
cancer realted 
pathways TCGA 
AATF 26574           
ABL1 25   Y   Y   
AKT1* 207 Y Y   Y Y 
AKT2 208   Y   Y   
ARAF 369       Y   
BAK1 578           
BCL2 596   Y   Y   
BCL2L11 10018           
BRAF 673   Y   Y   
BRCA1 672 Y Y Y   Y 
BRCA2 675 Y Y Y     
BRIP1* 83990 Y         
CDK5 1020           
CDKN1B 1027     Y Y Y 
CDKN2A 1029   Y Y   Y 
CHEK1 1111         Y 
CHUK 1147       Y   
DAXX 1616   Y   Y   
DMAP1 55929           
EP300 2033 Y Y Y Y   
FOXO3 2309   Y     Y 
GSK3B 2932       Y   
HGS 9146           
HSP90AB1 3326   Y   Y   
HSPB1 3315       Y   
IKBKB 3551       Y Y 
ING5 84289           
IRS1 3667     Y     
JAK2 3717   Y       
KAT2B 8850           
KRAS* 3845 Y Y Y Y   
MAP2K1 5604       Y   
MAP2K2 5605       Y   
MAP2K4 6416 Y Y   Y Y 
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MAP3K8 1326   Y   Y   
MAPK1 5594       Y   
MAPK10 5602       Y   
MAPK11 5600       Y   
MAPK3 5595       Y   
MAPK9 5601       Y   
MDM2 4193   Y Y     
MDM4 4194   Y       
MLL 4297   Y       
MSH2 4436   Y       
MTOR 2475       Y Y 
NF2 4771   Y       
NFKBIA 4792       Y Y 
NR3C1 2908     Y     
PAK1 5058       Y Y 
PDGFRB 5159   Y   Y   
PIAS4 51588           
PIK3CA* 5290 Y Y Y Y Y 
PIK3R1 5295   Y   Y Y 
PML 5371   Y       
PPM1D* 8493 Y         
PTGS2 5743     Y Y   
PTK2 5747       Y   
PTTG1 9232           
RAF1 5894   Y   Y   
RALGDS 5900   Y       
RASA1 5921   Y   Y   
RB1 5925 Y Y Y   Y 
RB1CC1* 9821 Y         
RPS6KB1 6198       Y Y 
S100A4 6275           
S100B 6285           
SLC22A18* 5002 Y Y       
SOS1 6654       Y   
SRC 6714   Y   Y   
TCL1A 8115   Y       
THRB 7068           
TP53* 7157 Y Y Y Y   
TP53BP1 7158           
108 
 
TP53INP1 94241           
TSC2 7249   Y       
TSG101* 7251 Y         
VEGFA 7422     Y Y   
VPS28 51160           
VPS36 51028           
VRK1 7443           
WWOX 51741   Y     Y 
YBX1 4904           
 
109 
 
APPENDIX F 
F
D
R
 
<
  
1
.0
0
E
-1
0
 
<
  
1
.0
0
E
-1
0
 
<
  
1
.0
0
E
-1
0
 
<
  
1
.0
0
E
-1
0
 
<
  
1
.0
0
E
-1
0
 
<
  
1
.0
0
E
-1
0
 
<
  
1
.0
0
E
-1
0
 
<
  
1
.0
0
E
-1
0
 
0
.0
0
0
7
7
9
6
9
1
 
p
-v
a
lu
e
 
<
  
1
.0
0
E
-1
0
 
<
  
1
.0
0
E
-1
0
 
<
  
1
.0
0
E
-1
0
 
<
  
1
.0
0
E
-1
0
 
<
  
1
.0
0
E
-1
0
 
<
  
1
.0
0
E
-1
0
 
<
  
1
.0
0
E
-1
0
 
<
  
1
.0
0
E
-1
0
 
0
.0
0
0
1
7
0
2
7
7
 
G
e
n
e
s 
G
S
K
3
B
, 
R
P
S
6
K
B
1
, 
P
IK
3
R
1
, 
A
K
T
1
, 
P
IK
3
C
A
, 
M
A
P
2
K
2
, 
R
A
F
1
, 
B
R
A
F
, 
A
B
L1
, 
S
O
S
1
, 
M
T
O
R
, 
M
A
P
K
1
, 
M
A
P
K
9
, 
P
A
K
1
, 
K
R
A
S
, 
A
R
A
F
, 
M
A
P
2
K
1
, 
A
K
T
2
, 
M
A
P
2
K
4
, 
C
D
K
N
1
B
, 
M
A
P
K
1
0
, 
S
R
C
, 
P
T
K
2
, 
M
A
P
K
3
 
H
S
P
B
1
, 
T
P
5
3
, 
A
K
T
1
, 
M
A
P
2
K
2
, 
R
A
F
1
, 
B
R
A
F
, 
S
O
S
1
, 
P
D
G
F
R
B
, 
M
A
P
K
1
, 
M
A
P
K
9
, 
M
A
P
K
1
1
, 
P
A
K
1
, 
K
R
A
S
, 
M
A
P
2
K
1
, 
IK
B
K
B
, 
M
A
P
3
K
8
, 
A
K
T
2
, 
R
A
S
A
1
, 
M
A
P
2
K
4
, 
C
H
U
K
, 
M
A
P
K
1
0
, 
D
A
X
X
, 
M
A
P
K
3
 
G
S
K
3
B
, 
P
IK
3
R
1
, 
V
E
G
F
A
, 
A
K
T
1
, 
P
IK
3
C
A
, 
R
A
F
1
, 
B
R
A
F
, 
S
O
S
1
, 
P
D
G
F
R
B
, 
M
A
P
K
1
, 
M
A
P
K
9
, 
P
A
K
1
, 
M
A
P
2
K
1
, 
A
K
T
2
, 
M
A
P
K
1
0
, 
S
R
C
, 
P
T
K
2
, 
B
C
L2
, 
M
A
P
K
3
 
H
S
P
B
1
, 
P
IK
3
R
1
, 
V
E
G
F
A
, 
A
K
T
1
, 
P
T
G
S
2
, 
P
IK
3
C
A
, 
M
A
P
2
K
2
, 
R
A
F
1
, 
M
A
P
K
1
, 
M
A
P
K
1
1
, 
K
R
A
S
, 
M
A
P
2
K
1
, 
A
K
T
2
, 
S
R
C
, 
P
T
K
2
, 
M
A
P
K
3
 
P
IK
3
R
1
, 
P
IK
3
C
A
, 
M
A
P
2
K
2
, 
R
A
F
1
, 
B
R
A
F
, 
S
O
S
1
, 
P
D
G
F
R
B
, 
M
A
P
K
1
, 
P
A
K
1
, 
K
R
A
S
, 
A
R
A
F
, 
M
A
P
2
K
1
, 
S
R
C
, 
P
T
K
2
, 
M
A
P
K
3
 
H
S
P
9
0
A
B
1
, 
P
IK
3
R
1
, 
A
K
T
1
, 
P
IK
3
C
A
, 
R
A
F
1
, 
B
R
A
F
, 
M
A
P
K
1
, 
M
A
P
K
9
, 
M
A
P
K
1
1
, 
K
R
A
S
, 
A
R
A
F
, 
M
A
P
2
K
1
, 
A
K
T
2
, 
M
A
P
K
1
0
, 
M
A
P
K
3
 
M
A
P
2
K
2
, 
R
A
F
1
, 
S
O
S
1
, 
M
A
P
K
1
, 
M
A
P
K
9
, 
M
A
P
K
1
1
, 
K
R
A
S
, 
M
A
P
2
K
1
, 
M
A
P
2
K
4
, 
M
A
P
K
1
0
, 
S
R
C
, 
M
A
P
K
3
 
P
IK
3
R
1
, 
T
P
5
3
, 
A
K
T
1
, 
P
IK
3
C
A
, 
IK
B
K
B
, 
A
K
T
2
, 
C
H
U
K
, 
B
C
L2
, 
N
F
K
B
IA
 
E
P
3
0
0
, 
M
A
P
K
1
, 
S
R
C
, 
M
A
P
K
3
 
N
u
m
b
e
r 
o
f 
g
e
n
e
s 
in
 b
re
a
st
 
ca
n
ce
r 
m
o
d
u
le
 
2
4
 
2
3
 
1
9
 
1
6
 
1
5
 
1
5
 
1
2
 
9
 
4
 
K
E
G
G
 p
a
th
w
a
y
  
E
rb
B
 s
ig
n
a
li
n
g
 
p
a
th
w
a
y
 
M
A
P
K
 s
ig
n
a
li
n
g
 
p
a
th
w
a
y
 
F
o
ca
l 
a
d
h
e
si
o
n
 
V
E
G
F
 s
ig
n
a
li
n
g
 
p
a
th
w
a
y
 
R
e
g
u
la
ti
o
n
 o
f 
a
ct
in
 c
y
to
sk
e
le
to
n
 
P
ro
g
e
st
e
ro
n
e
-
m
e
d
ia
te
d
 o
o
cy
te
 
m
a
tu
ra
ti
o
n
 
G
n
R
H
 s
ig
n
a
li
n
g
 
p
a
th
w
a
y
 
A
p
o
p
to
si
s 
A
d
h
e
re
n
s 
ju
n
ct
io
n
 
110 
 
APPENDIX G 
Gene 
Symbol 
Entrez 
ID 
Known 
drivers in 
ovarian 
cancer 
Drivers in 
other 
cancer 
types 
Candidate 
drivers 
identified by 
GWAS 
Involved in 
cancer 
realted 
pathways TCGA 
ABL1 25   Y   Y Y 
AKT1* 207 Y Y   Y Y 
APC 324   Y   Y   
BRAF 673   Y   Y   
CBLL1 79872           
CDH1* 999 Y Y   Y Y 
CDK5 1020         Y 
CSK 1445           
CTNNB1* 1499 Y Y   Y   
EGFR 1956   Y   Y   
ERBB2* 2064 Y Y   Y   
ERBB2IP 55914           
ERBB3 2065       Y   
ERBB4 2066       Y   
ESR1 2099   Y Y     
FYN 2534       Y   
GSK3B 2932       Y   
IGF1R 3480       Y Y 
IKBKB 3551       Y   
INSR 3643       Y   
JAK2 3717   Y       
KLRG1 10219           
LCK 3932   Y       
MAP2K1 5604       Y   
MAP2K2 5605       Y   
MAP2K4 6416   Y   Y   
MAP3K1 4214       Y   
MAPK1 5594       Y   
MAPK14 1432       Y   
MAPK3 5595       Y   
MDM4 4194   Y       
MLST8 64223           
MRTO4 51154           
MTOR 2475       Y   
111 
 
NCOA7 135112           
NOC2L 26155           
PDE3B 5140       Y   
PIK3CA* 5290 Y Y   Y   
PIK3R1 5295 Y Y   Y Y 
PRKCA 5578       Y   
PTK2 5747       Y   
PTK2B 2185       Y   
PTK6 5753         Y 
RAF1 5894   Y   Y Y 
RRAS2* 22800 Y     Y   
SRC 6714   Y   Y   
ST5 6764           
TCF7L1 83439       Y   
TCF7L2 6934   Y   Y Y 
THOC3 84321           
TJP1 7082       Y   
TRAF3IP2 10758           
WDR12 55759           
WDR31 114987           
WDR51A 25886         Y 
WDR51B 282809           
WDR69 164781           
WNK1 65125         Y 
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